<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>JOLESSA - levonorgestrel and ethinyl estradiol 
			 </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">Rx <span class="Bold">only</span></p>
<p>11001623<br>Revised February 2010</p>
<p><span class="Bold">Jolessa<span class="Sup">™</span> (levonorgestrel / ethinyl 
estradiol tablets) 0.15 mg / 0.03 mg</span></p>
<p><span class="Bold">Patients should be counseled that this product does not 
protect against HIV-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (AIDS) and other sexually transmitted 
diseases.</span></p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<a href="http://"></a><p class="First"><span class="Bold">Cigarette smoking increases the risk of serious 
cardiovascular side effects from oral contraceptive use. This risk increases 
with age and with heavy smoking (15 or more cigarettes per day) and is quite 
marked in women over 35 years of age. Women who use oral contraceptives should 
be strongly advised not to smoke.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Jolessa<span class="Sup">™</span> (levonorgestrel/ethinyl estradiol 
tablets) is an extended-cycle oral contraceptive consisting of 84 pink active 
tablets each containing 0.15 mg of levonorgestrel, a synthetic progestogen and 
0.03 mg of ethinyl estradiol, and 7 white inert tablets (without hormones).</p>
<p>The chemical formula of levonorgestrel USP is 
18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-, (-)-, and the 
chemical formula of ethinyl estradiol USP is 
19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-. The structural formulas 
are as follows:</p>
<a name="ib083818d-7538-434f-8c7b-275e29cc2174"></a><table width="50%"><tbody class="Headless">
<tr class="First">
<td><img alt="image of Levonorgestrel chemcial structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=709031e4-4c20-4ea7-beff-6c459709a433&amp;name=chemical%20structure%201.jpg"></td>
<td><p class="First">Levonorgestrel C<span class="Sub">21</span>H<span class="Sub">28</span>O<span class="Sub">2</span> MW: 312.4</p></td>
</tr>
<tr>
<td><img alt="image of Ethinyl Estradiol chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=709031e4-4c20-4ea7-beff-6c459709a433&amp;name=chemical%20structure%202.jpg"></td>
<td><p class="First">Ethinyl Estradiol C<span class="Sub">20</span>H<span class="Sub">24</span>O<span class="Sub">2</span> MW: 296.4</p></td>
</tr>
<tr class="Last">
<td><br></td>
<td><br></td>
</tr>
</tbody></table>
<br><p>Each pink active tablet contains the following inactive ingredients: 
anhydrous lactose NF, FD&amp;C blue no. 1, FD&amp;C red no. 40, hydroxypropyl 
methylcellulose USP, microcrystalline cellulose NF, polyethylene glycol NF, 
magnesium stearate NF, polysorbate 80 NF, and titanium dioxide USP. Each white 
inert tablet contains the following inactive ingredients: anhydrous lactose NF, 
hydroxypropyl methylcellulose USP, microcrystalline cellulose NF, and magnesium 
stearate NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="http://"></a>Mode of action<p class="First">Combination oral contraceptives act by suppression of 
gonadotropins. Although the primary mechanism of this action is inhibition of 
ovulation, other alterations include changes in the cervical mucus (which 
increase the difficulty of sperm entry into the uterus) and changes in the 
endometrium (which reduce the likelihood of implantation).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pharmacokinetics<a href="http://"></a><a href="http://"></a><a href="http://"></a>Absorption<p>No specific investigation of the absolute bioavailability of 
Jolessa<span class="Sup">™</span> in humans has been conducted. However, 
literature indicates that levonorgestrel is rapidly and completely absorbed 
after oral administration (bioavailability nearly 100%) and is not subject to 
first-pass metabolism. Ethinyl estradiol is rapidly and almost completely 
absorbed from the gastrointestinal tract but, due to first-pass metabolism in 
gut mucosa and liver, the bioavailability of ethinyl estradiol is approximately 
43%.</p>
<a href="http://"></a><a name="ie77dbe05-ced5-46b2-8070-547ef74a9505"></a><table width="0.000">
<caption><span>Table 1: Mean ± SD Pharmacokinetic Parameters Following A Single Dose 
Administration of Two Tablets of Jolessa™ in Healthy Female Subjects Under 
Fasting Conditions</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Analyte</span></td>
<td>
<span class="Bold">AUC<span class="Sub">t</span></span><br><span class="Bold">(mean </span>± <span class="Bold">SD)</span>
</td>
<td>
<span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold">(mean </span>± <span class="Bold">SD)</span>
</td>
<td>
<span class="Bold">T<span class="Sub">max</span></span><br><span class="Bold">(mean </span>± <span class="Bold">SD)</span>
</td>
<td>
<span class="Bold">T<span class="Sub">1/2</span></span><br><span class="Bold">(mean </span>± <span class="Bold">SD)</span>
</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>60.8 ± 25.6<br>ng*hr/mL</td>
<td>5.6 ± 1.5<br>ng/mL</td>
<td>1.4 ± 0.3 hours</td>
<td>29.8 ± 8.3<br>hours</td>
</tr>
<tr class="Last">
<td>Ethinyl estradiol</td>
<td>1307 ± 361<br>pg*hr/mL</td>
<td>145 ± 45<br>pg/mL</td>
<td>1.6 ± 0.5 hours</td>
<td>15.4 ± 
3.2<br>hours</td>
</tr>
</tbody>
</table>
<p>The effect of food on the rate and the extent of levonorgestrel and ethinyl 
estradiol absorption following oral administration of Jolessa<span class="Sup">™</span> has not been evaluated.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Distribution<p>The apparent volume of distribution of levonorgestrel and ethinyl 
estradiol are reported to be approximately 1.8 L/kg and 4.3 L/kg, respectively. 
Levonorgestrel is about 97.5 - 99% protein-bound, principally to sex hormone 
binding globulin (SHBG) and, to a lesser extent, serum albumin. Ethinyl 
estradiol is about 95 - 97% bound to serum albumin. Ethinyl estradiol does not 
bind to SHBG, but induces SHBG synthesis, which leads to decreased 
levonorgestrel clearance. Following repeated daily dosing of combination 
levonorgestrel/ethinyl estradiol oral contraceptives, levonorgestrel plasma 
concentrations accumulate more than predicted based on single-dose kinetics, due 
in part, to increased SHBG levels that are induced by ethinyl estradiol, and a 
possible reduction in hepatic metabolic capacity.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Metabolism<p>Following absorption, levonorgestrel is conjugated at the 17β-OH 
position to form sulfate and to a lesser extent, glucuronide conjugates in 
plasma. Significant amounts of conjugated and unconjugated 
3α,5β-tetrahydrolevonorgestrel are also present in plasma, along with much 
smaller amounts of 3α,5α-tetrahydrolevonorgestrel and 16β-hydroxylevonorgestrel. 
Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide 
conjugates. Metabolic clearance rates may differ among individuals by 
several-fold, and this may account in part for the wide variation observed in 
levonorgestrel concentrations among users.</p>
<p>First-pass metabolism of ethinyl estradiol involves formation of ethinyl 
estradiol-3-sulfate in the gut wall, followed by 2-hydroxylation of a portion of 
the remaining untransformed ethinyl estradiol by hepatic cytochrome P-450 3A4 
(CYP3A4). Levels of CYP3A4 vary widely among individuals and can explain the 
variation in rates of ethinyl estradiol hydroxylation. Hydroxylation at the 4-, 
6-, and 16- positions may also occur, although to a much lesser extent than 
2-hydroxylation. The various hydroxylated metabolites are subject to further 
methylation and/or conjugation.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Excretion<p>About 45% of levonorgestrel and its metabolites are excreted in 
the urine and about 32% are excreted in feces, mostly as glucuronide conjugates. 
The terminal elimination half-life for levonorgestrel after a single dose of 
Jolessa<span class="Sup">™</span> was about 30 hours.</p>
<p>Ethinyl estradiol is excreted in the urine and feces as glucuronide and 
sulfate conjugates, and it undergoes enterohepatic recirculation. The terminal 
elimination half-life of ethinyl estradiol after a single dose of Jolessa<span class="Sup">™</span> was found to be about 15 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4"></a><p></p>
<h1>SPECIAL POPULATIONS</h1>
<a href="http://"></a>Race<p class="First">No formal studies on the effect of race on the pharmacokinetics 
of Jolessa<span class="Sup">™</span> were conducted.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span><p>No formal studies have been conducted to evaluate the effect of 
<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the pharmacokinetics of Jolessa<span class="Sup">™</span>. 
However, steroid hormones may be poorly metabolized in patients with impaired 
liver function.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span><p>No formal studies have been conducted to evaluate the effect of 
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the pharmacokinetics of Jolessa<span class="Sup">™</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Drug-Drug Interactions<p><span class="Bold">See <a href="#i4i_precautions_id_4c71e74e-f3c2-4f5c-83b2-b016d0f3d093">PRECAUTIONS</a> 
section – <a href="#i4i_interactions_id_83326a02-dc30-474d-a4cc-62fd1c693493">Drug 
Interactions</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Jolessa<span class="Sup">™</span> tablets are indicated for the 
prevention of pregnancy in women who elect to use oral contraceptives as a 
method of contraception.</p>
<p>In a 1-year controlled clinical trial, 4 pregnancies occurred in women 18-35 
years of age during 809 completed 91-day cycles of Jolessa<span class="Sup">™</span> during which no backup contraception was utilized. This 
represents an overall use-efficacy (typical user efficacy) pregnancy rate of 
1.98 per 100 women-years of use.</p>
<p>Oral contraceptives are highly effective for pregnancy prevention. Table 2 
lists the typical <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> rates for users of combination oral 
contraceptives and other methods of contraception. The efficacy of these 
contraceptive methods, except sterilization, the IUD, and Norplant<span class="Sup">®</span> Implant System, depends upon the reliability with which they 
are used. Correct and consistent use of methods can result in lower failure 
rates.</p>
<a href="http://"></a><a name="i7bf12cab-a838-43b0-877a-6836a3e2d04f"></a><table width="482">
<caption><span>TABLE 2 Percentage of women experiencing an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> during 
the first year of typical use and the first year of perfect use of contraception 
and the percentage continuing use at the end of the first year: United 
States.</span></caption>
<col width="35%">
<col width="19%">
<col width="22%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>% of Women Experiencing 
an <br><span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">Unintended Pregnancy</span> <br>within the First Year of Use</td>
<td>% of Women Continuing Use at One 
Year<a href="#footnote-1">*</a>
</td>
</tr>
<tr>
<td>Method<br>(1)</td>
<td>Typical Use<a href="#footnote-2">†</a><br>(2)</td>
<td>Perfect Use<a href="#footnote-3">‡</a><br>(3)</td>
<td>
<br>(4)</td>
</tr>
<tr>
<td>Chance<a href="#footnote-4">§</a> </td>
<td>85</td>
<td>85</td>
<td><br></td>
</tr>
<tr>
<td>Spermicides<a href="#footnote-5">¶</a> </td>
<td>26</td>
<td>6</td>
<td>40</td>
</tr>
<tr>
<td>Periodic abstinence</td>
<td>25</td>
<td><br></td>
<td>63</td>
</tr>
<tr>
<td>   Calendar</td>
<td><br></td>
<td>9</td>
<td><br></td>
</tr>
<tr>
<td>   Ovulation method</td>
<td><br></td>
<td>3</td>
<td><br></td>
</tr>
<tr>
<td>   Sympto-thermal <a href="#footnote-6">#</a> </td>
<td><br></td>
<td>2</td>
<td><br></td>
</tr>
<tr>
<td>   Post-ovulation</td>
<td><br></td>
<td>1</td>
<td><br></td>
</tr>
<tr>
<td>Withdrawal</td>
<td>19</td>
<td>4</td>
<td><br></td>
</tr>
<tr>
<td>Cap <a href="#footnote-7">Þ</a> </td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>   Parous women</td>
<td>40</td>
<td>26</td>
<td>42</td>
</tr>
<tr>
<td>   Nulliparous women</td>
<td>20</td>
<td>9</td>
<td>56</td>
</tr>
<tr>
<td>Sponge</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>   Parous women</td>
<td>40</td>
<td>20</td>
<td>42</td>
</tr>
<tr>
<td>   Nulliparous women</td>
<td>20</td>
<td>9</td>
<td>56</td>
</tr>
<tr>
<td>Diaphragm <a href="#footnote-7">Þ</a> </td>
<td>20</td>
<td>6</td>
<td>56</td>
</tr>
<tr>
<td>Condom <a href="#footnote-8">ß</a>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>   Female (Reality)</td>
<td>21</td>
<td>5</td>
<td>56</td>
</tr>
<tr>
<td>   Male</td>
<td>14</td>
<td>3</td>
<td>61</td>
</tr>
<tr>
<td>Pill</td>
<td>5</td>
<td><br></td>
<td>71</td>
</tr>
<tr>
<td>   Progestin only</td>
<td><br></td>
<td>0.5</td>
<td><br></td>
</tr>
<tr>
<td>   Combined</td>
<td><br></td>
<td>0.1</td>
<td><br></td>
</tr>
<tr>
<td>IUD:</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>   Progesterone T</td>
<td>2.0</td>
<td>1.5</td>
<td>81</td>
</tr>
<tr>
<td>   Copper T 380A</td>
<td>0.8</td>
<td>0.6</td>
<td>78</td>
</tr>
<tr>
<td>   LNg 20</td>
<td>0.1</td>
<td>0.1</td>
<td>81</td>
</tr>
<tr>
<td>Depo Provera</td>
<td>0.3</td>
<td>0.3</td>
<td>70</td>
</tr>
<tr>
<td>Norplant and Norplant-2</td>
<td>0.05</td>
<td>0.05</td>
<td>88</td>
</tr>
<tr>
<td>Female sterilization</td>
<td>0.5</td>
<td>0.5</td>
<td>100</td>
</tr>
<tr class="Last">
<td>Male sterilization</td>
<td>0.15</td>
<td>0.10</td>
<td>100</td>
</tr>
</tbody>
</table>
<span class="Bold">Emergency Contraceptive Pills: </span>Treatment initiated 
within 72 hours after unprotected intercourse reduces the risk of pregnancy by 
at least 75%. <a href="#footnote-9">à</a><br><span class="Bold">Lactational <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> Method: </span>LAM is a highly 
effective, <span class="Italics">temporary</span> method of contraception. <a href="#footnote-10">è</a><br>Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart 
F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth 
Revised Edition. New York NY: Irvington Publishers, 1998.<br><a href="#footnote-reference-1">*</a>Among couples attempting to avoid pregnancy, the percentage who continue to 
use a method for one year.<a href="#footnote-reference-2">†</a>Among typical couples who initiate use of a method (not necessarily for the 
first time), the percentage who experience an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> during the 
first year if they do not stop use for any other reason.<a href="#footnote-reference-3">‡</a>Among couples who initiate use of a method (not necessarily for the first 
time) and who use it perfectly (both consistently and correctly), the percentage 
who experience an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> during the first year if they do not stop 
use for any other reason.<a href="#footnote-reference-4">§</a>The percentages of women becoming pregnant in columns (2) and (3) are based 
on data from populations where contraception is not used and from women who 
cease using contraception in order to become pregnant. Among such populations, 
about 89% become pregnant within one year. This estimate was lowered slightly 
(to 85%) to represent the percentage who would become pregnant within one year 
among women now relying on reversible methods of contraception if they abandoned 
contraception altogether.<a href="#footnote-reference-5">¶</a>Foams, creams, gels, vaginal suppositories and vaginal film.<a href="#footnote-reference-6">#</a>Cervical mucus (ovulation) method supplemented by calendar in the 
pre-ovulatory and basal body temperature in the post-ovulatory phases.<a href="#footnote-reference-7">Þ</a>With spermicidal cream or jelly.<a href="#footnote-reference-8">ß</a>Without spermicides.<a href="#footnote-reference-9">à</a>The treatment schedule is one dose within 72 hours after unprotected 
intercourse and a second dose 12 hours after the first dose. The Food and Drug 
Administration has declared the following brands of oral contraceptives to be 
safe and effective for emergency contraception: Ovral (1 dose is 2 white pills), 
Alesse (1 dose is 5 pink pills), Nordette or Levlen (1 dose is 2 light-orange 
pills), Lo/Ovral (1 dose is 4 white pills), Triphasil or Tri-Levlen (1 dose is 4 
yellow pills).<a href="#footnote-reference-10">è</a>However, to maintain effective protection against pregnancy, another method 
of contraception must be used as soon as menstruation resumes, the frequency or 
duration of breastfeeds is reduced, bottle feeds are introduced or the baby 
reaches six months of age.<br><br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Oral contraceptives should not be used in women who currently 
have the following conditions:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> or thromboembolic disorders</li>
<li>A past history of deep vein <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or thromboembolic 
disorders</li>
<li>Cerebrovascular or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (current or history)</li>
<li><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> with thrombogenic complications</li>
<li><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span></li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> with vascular involvement</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> with focal neurological symptoms</li>
<li>Major surgery with prolonged immobilization</li>
<li>Known or suspected carcinoma of the breast or personal history of breast 
cancer</li>
<li>Carcinoma of the endometrium or other known or suspected estrogen-dependent 
neoplasia</li>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> of pregnancy or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with prior pill use</li>
<li><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or carcinomas, or active liver disease</li>
<li>Known or suspected pregnancy</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product</li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a><p class="First"><span class="Bold">Cigarette smoking increases the risk of serious 
cardiovascular side effects from oral contraceptive use. This risk increases 
with age and with heavy smoking (15 or more cigarettes per day) and is quite 
marked in women over 35 years of age. Women who use oral contraceptives should 
be strongly advised not to smoke.</span></p>
<a href="http://"></a><a href="http://"></a><p>The use of oral contraceptives is associated with increased risk 
of several serious conditions including venous and arterial thrombotic and 
<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>), <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasia</span>, <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The risk of 
serious morbidity or mortality is very small in healthy women without underlying 
risk factors. The risk of morbidity and mortality increases significantly in the 
presence of other underlying risk factors such as certain inherited 
<span class="product-label-link" type="condition" conceptid="4125650" conceptname="Thrombophilia">thrombophilias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
<p>Practitioners prescribing oral contraceptives should be familiar with the 
following information relating to these risks. The information contained in this 
package insert is principally based on studies carried out in patients who used 
oral contraceptives with higher formulations of estrogens and progestogens than 
those in common use today. The effect of longterm use of the oral contraceptives 
with lower doses of both estrogens and progestogens remains to be 
determined.</p>
<p>Throughout this labeling, epidemiological studies reported are of two types: 
retrospective or case control studies and prospective or cohort studies. Case 
control studies provide a measure of the relative risk of a disease, namely, a 
ratio of the incidence of a disease among oral contraceptive users to that among 
nonusers. The relative risk does not provide information on the actual clinical 
occurrence of a disease. Cohort studies provide a measure of attributable risk, 
which is the difference in the incidence of disease between oral contraceptive 
users and nonusers. The attributable risk does provide information about the 
actual occurrence of a disease in the population. For further information, the 
reader is referred to a text on epidemiological methods.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>1. Thromboembolic Disorders and Other Vascular 
Problems<p>Use of Jolessa™ provides women with more hormonal exposure on a 
yearly basis than conventional monthly oral contraceptives containing similar 
strength synthetic estrogens and progestins (an additional 9 weeks per year). 
While this added exposure may pose an additional risk of thrombotic and 
thromboembolic disease, studies to date with Jolessa™ have not suggested an 
increased risk of these disorders.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">a. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span><p>An increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been attributed to 
oral contraceptive use. This risk is primarily in smokers or women with other 
underlying risk factors for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">morbid obesity</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The relative risk of heart 
attack for current oral contraceptive users has been estimated to be two to six. 
The risk is very low under the age of 30. Smoking in combination with oral 
contraceptive use has been shown to contribute substantially to the incidence of 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in women in their mid-thirties or older with smoking 
accounting for the majority of excess cases. Mortality rates associated with 
circulatory disease have been shown to increase substantially in smokers over 
the age of 35 and <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> over the age of 40 (Figure 1) among women who use 
oral contraceptives.</p>
<p><img alt="image of figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=709031e4-4c20-4ea7-beff-6c459709a433&amp;name=figure%201.jpg"></p>
<p></p>
<p>Figure 1 Adapted from P.M. Layde and B Beral, Lancet, 
1 :541-546,1981</p>
<p>Oral contraceptives may compound the effects of well-known risk factors, such 
as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, age and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. In particular, some 
progestogens are known to decrease HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and cause glucose 
intolerance, while estrogens may create a state of <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span>. Oral 
contraceptives have been shown to increase blood pressure among users (see 
section 9 in <span class="Bold"><a href="#i4i_warnings_id_ac69b5b4-1bf6-4e89-b332-699adaa3ca1c">WARNINGS</a></span>). 
The severity and number of risk factors increase heart disease risk. Oral 
contraceptives must be used with caution in women with cardiovascular disease 
risk factors.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">b. <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span>:</span><p>An increased risk of thromboembolic and thrombotic disease 
associated with the use of oral contraceptives is well established. Case control 
studies have found the relative risk of users compared to nonusers to be 3 for 
the first episode of superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, 4 to 11 for deep vein 
<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and 1.5 to 6 for women with predisposing 
conditions for venous thromboembolic disease. Cohort studies have shown the 
relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new 
cases requiring hospitalization. The approximate incidence of deep vein 
<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> in users of low dose (&lt;50 μg ethinyl 
estradiol) combination oral contraceptives is up to 4 per 10,000 woman-years 
compared to 0.5-3 per 10,000 woman-years for non-users. However, the incidence 
is less than that associated with pregnancy (6 per 10,000 woman-years). The risk 
of thromboembolic disease due to oral contraceptives is not related to length of 
use and disappears after pill use is stopped.</p>
<p>A two- to four-fold increase in relative risk of postoperative thromboembolic 
complications has been reported with the use of oral contraceptives. The 
relative risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> in women who have predisposing conditions is 
twice that of women without such medical conditions. If feasible, oral 
contraceptives should be discontinued at least four weeks prior to and for two 
weeks after elective surgery of a type associated with an increase in risk of 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and during and following prolonged immobilization. Since the 
immediate postpartum period is also associated with an increased risk of 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, oral contraceptives should be started no earlier than four 
weeks after delivery in women who elect not to breast-feed.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">c. Cerebrovascular 
Diseases:</span><p>Oral contraceptives have been shown to increase both the relative 
and attributable risks of cerebrovascular events (thrombotic and hemorrhagic 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>), although, in general, the risk is greatest among older (&gt;35 years), 
hypertensive women who also smoke. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was found to be a risk factor 
for both users and nonusers, for both types of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while smoking interacted 
to increase the risk for <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>.</p>
<p>In a large study, the relative risk of <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">thrombotic strokes</span> has been shown to 
range from 3 for normotensive users to 14 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. 
The relative risk of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> is reported to be 1.2 for <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> who 
used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 
7.6 for smokers who used oral contraceptives, 1.8 for normotensive users and 
25.7 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The attributable risk is also greater 
in older women. Oral contraceptives also increase the risk for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women 
with other underlying risk factors such as certain inherited or acquired 
<span class="product-label-link" type="condition" conceptid="4125650" conceptname="Thrombophilia">thrombophilias</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. Women with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (particularly 
<span class="product-label-link" type="condition" conceptid="381549" conceptname="Migraine with aura">migraine with aura</span>) who take combination oral contraceptives may be at an 
increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">d. Dose-Related Risk of Vascular 
Disease from Oral Contraceptives: </span><p>A positive association has been observed between the amount of 
estrogen and progestogen in oral contraceptives and the risk of vascular 
disease. A decline in serum high-density lipoproteins (HDL) has been reported 
with many progestational agents. A decline in serum high-density lipoproteins 
has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>.</p>
<p>Because estrogens increase HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, the net effect of an oral 
contraceptive depends on a balance achieved between doses of estrogen and 
progestogen and the nature and absolute amount of progestogen used in the 
contraceptive. The amount of both hormones should be considered in the choice of 
an oral contraceptive.</p>
<p>Minimizing exposure to estrogen and progestogen is in keeping with good 
principles of therapeutics. For any particular estrogen/progestogen combination, 
the dosage regimen prescribed should be one which contains the least amount of 
estrogen and progestogen that is compatible with a low failure rate and the 
needs of the individual patient. New acceptors of oral contraceptive agents 
should be started on preparations containing the lowest estrogen content which 
is judged appropriate for the individual patient.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">e. Persistence of Risk of 
Vascular Disease:</span><p>There are two studies which have shown persistence of risk of 
vascular disease for ever-users of oral contraceptives. In a study in the United 
States, the risk of developing <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> after discontinuing oral 
contraceptives persists for at least 9 years for women 40 to 49 years old who 
had used oral contraceptives for five or more years, but this increased risk was 
not demonstrated in other age groups. In another study in Great Britain, the 
risk of developing cerebrovascular disease persisted for at least 6 years after 
discontinuation of oral contraceptives, although excess risk was very small. 
However, both studies were performed with oral contraceptive formulations 
containing 50 micrograms or higher of estrogens.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>2. Estimates of Mortality from Contraceptive Use<p>One study gathered data from a variety of sources which have 
estimated the mortality rate associated with different methods of contraception 
at different ages (Table 3). These estimates include the combined risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> 
associated with contraceptive methods plus the risk attributable to pregnancy in 
the event of method failure. Each method of contraception has its specific 
benefits and risks. The study concluded that with the exception of oral 
contraceptive users 35 and older who smoke and 40 and older who do not smoke, 
mortality associated with all methods of birth control is less than that 
associated with childbirth. The observation of a possible increase in risk of 
mortality with age for oral contraceptive users is based on data gathered in the 
1970’s—but not reported until 1983. However, current clinical practice involves 
the use of lower estrogen dose formulations combined with careful restriction of 
oral contraceptive use to women who do not have the various risk factors listed 
in this labeling.</p>
<p>Because of these changes in practice and, also, because of some limited new 
data which suggest that the risk of cardiovascular disease with the use of oral 
contraceptives may now be less than previously observed, the Fertility and 
Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. 
The Committee concluded that although cardiovascular disease risks may be 
increased with oral contraceptive use after age 40 in healthy nonsmoking women 
(even with the newer low-dose formulations), there are greater potential health 
risks associated with pregnancy in older women and with the alternative surgical 
and medical procedures which may be necessary if such women do not have access 
to effective and acceptable means of contraception.</p>
<p>Therefore, the Committee recommended that the benefits of oral contraceptive 
use by healthy nonsmoking women over 40 may outweigh the possible risks. Of 
course, older women, as all women who take oral contraceptives, should take the 
lowest possible dose formulation that is effective.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<p class="First"></p>
<p>that is effective.</p>
<a href="http://"></a><a name="i0a399709-a6f1-4eba-8a92-302046104c83"></a><table width="467">
<caption><span>TABLE 3: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> 
ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY 
FERTILITY-CONTROL METHOD AND ACCORDING TO AGE</span></caption>
<col width="29%">
<col width="11%">
<col width="11%">
<col width="12%">
<col width="10%">
<col width="10%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td>Method of control and 
outcome</td>
<td>
<br>15-19</td>
<td>
<br>20-24</td>
<td>AGE<br>25-29 </td>
<td>
<br>30-34</td>
<td>
<br>35-39</td>
<td>
<br>40-44</td>
</tr>
<tr>
<td>No fertility -<br> control 
methods<a href="#footnote-11">*</a>
</td>
<td>7.0</td>
<td>7.4</td>
<td>9.1</td>
<td>14.8</td>
<td>25.7</td>
<td>28.2</td>
</tr>
<tr>
<td>Oral 
contraceptives<br> non-smoker<a href="#footnote-12">†</a>
</td>
<td>0.3</td>
<td>0.5</td>
<td>0.9</td>
<td>1.9</td>
<td>13.8</td>
<td>31.6</td>
</tr>
<tr>
<td>Oral 
contraceptives<br> smoker<a href="#footnote-12">†</a>
</td>
<td>2.2</td>
<td>3.4</td>
<td>6.6</td>
<td>13.5</td>
<td>51.1</td>
<td>117.2</td>
</tr>
<tr>
<td>IUD<a href="#footnote-12">†</a>
</td>
<td>0.8</td>
<td>0.8</td>
<td>1.0</td>
<td>1.0</td>
<td>1.4</td>
<td>1.4</td>
</tr>
<tr>
<td>Condom<a href="#footnote-11">*</a>
</td>
<td>1.1</td>
<td>1.6</td>
<td>0.7</td>
<td>0.2</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Diaphragm/<br> spermicide<a href="#footnote-11">*</a>
</td>
<td>1.9</td>
<td>1.2</td>
<td>1.2</td>
<td>1.3</td>
<td>2.2</td>
<td>2.8</td>
</tr>
<tr class="Last">
<td>Periodic abstinence<a href="#footnote-11">*</a>
</td>
<td>2.5</td>
<td>1.6</td>
<td>1.6</td>
<td>1.7</td>
<td>2.9</td>
<td>3.6</td>
</tr>
</tbody>
</table>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Adapted from H.W. Ory, Family Planning Perpectives, 15:57-63, 1983.<br><a href="#footnote-reference-11">*</a><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth related<a href="#footnote-reference-12">†</a><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method related<br><br>3. Carcinoma of the Reproductive Organs and 
Breasts<p>Numerous epidemiological studies have been performed on the 
incidence of breast, endometrial, ovarian and cervical cancer in women using 
oral contraceptives. Although the risk of having breast cancer diagnosed may be 
slightly increased among current and recent users of combined oral 
contraceptives (RR=1.24), this excess risk decreases over time after combination 
oral contraceptive discontinuation and by 10 years after cessation the increased 
risk disappears. The risk does not increase with duration of use and no 
consistent relationships have been found with dose or type of steroid. The 
patterns of risk are also similar regardless of a woman’s reproductive history 
or her family breast cancer history. The subgroup for whom risk has been found 
to be significantly elevated is women who first used oral contraceptives before 
age 20, but because breast cancer is so rare at these young ages, the number of 
cases attributable to this early oral contraceptive use is extremely small. 
Breast cancers diagnosed in current or previous oral contraceptive users tend to 
be less clinically advanced than in never-users. Women who currently have or 
have had breast cancer should not use oral contraceptives because breast cancer 
is a hormone sensitive tumor.</p>
<p>Some studies suggest that oral contraceptive use has been associated with an 
increase in the risk of <span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">cervical intraepithelial neoplasia</span> or invasive cervical 
cancer in some populations of women. However, there continues to be controversy 
about the extent to which such findings may be due to differences in sexual 
behavior and other factors. In spite of many studies of the relationship between 
oral contraceptive use and breast cancer and cervical cancers, a cause 
and-effect relationship has not been established.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Hepatic Neoplasia</span><p>Benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> are associated with oral contraceptive 
use, although their occurrence is rare in the United States. Indirect 
calculations have estimated the attributable risk to be in the range of 3.3 
cases/100,000 for users, a risk that increases after four or more years of use. 
Rupture of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intra-abdominal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>Studies from Britain have shown an increased risk of developing 
hepatocellular carcinoma in long-term (&gt;8 years) oral contraceptive users. 
However, these cancers are extremely rare in the U.S., and the attributable risk 
(the excess incidence) of liver cancers in oral contraceptive users approaches 
less than one per million users.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>5. Ocular Lesions<p>There have been clinical case reports of retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> 
associated with the use of oral contraceptives that may lead to partial or 
complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>. Oral contraceptives should be discontinued if there is 
unexplained partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>; onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span> or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>; 
<span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>; or retinal vascular lesions. Appropriate diagnostic and therapeutic 
measures should be undertaken immediately.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>6. Oral contraceptive Use Before or During Early 
Pregnancy<p>Because women using Jolessa<span class="Sup">™</span> will likely 
have <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> only 4 times per year, pregnancy should be ruled out at 
the time of any missed menstrual period (see <span class="Bold"><a href="#i4i_dosage_admin_id_a5e2c96f-71d3-4a6f-8395-3dcb13e084e9">DOSAGE AND 
ADMINISTRATION</a></span> section). Oral contraceptive use should be 
discontinued if pregnancy is confirmed.</p>
<p>Extensive epidemiological studies have revealed no increased risk of birth 
defects in women who have used oral contraceptives prior to pregnancy. Studies 
also do not suggest a teratogenic effect, particularly in so far as cardiac 
anomalies and limb-reduction defects are concerned, when taken inadvertently 
during early pregnancy (see <span class="Bold"><a href="#i4i_contraindications_id_81c55af3-9c39-4f1a-a5c6-94d20e2d9729">CONTRAINDICATIONS</a></span> 
section).</p>
<p>The administration of oral contraceptives to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> 
should not be used as a test for pregnancy. Oral contraceptives should not be 
used during pregnancy to treat threatened or habitual abortion.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span><p>Earlier studies have reported an increased lifetime relative risk 
of gallbladder surgery in users of oral contraceptives and estrogens. More 
recent studies, however, have shown that the relative risk of developing 
<span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> among oral contraceptive users may be minimal. The recent 
findings of minimal risk may be related to the use of oral contraceptive 
formulations containing lower hormonal doses of estrogens and 
progestogens.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>8. Carbohydrate and Lipid Metabolic Effects<p>Oral contraceptives have been shown to cause <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> 
in a significant percentage of users. Oral contraceptives containing greater 
than 75 micrograms of estrogens cause <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span>, while lower doses of 
estrogen cause less <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>. Progestogens increase insulin secretion 
and create <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>, this effect varying with different progestational 
agents. However, in the nondiabetic woman, oral contraceptives appear to have no 
effect on fasting blood glucose. Because of these demonstrated effects, 
prediabetic and diabetic women should be carefully observed while taking oral 
contraceptives.</p>
<p>A small proportion of women will have persistent <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> while 
on the pill. As discussed earlier (see <span class="Bold"><a href="#i4i_warnings_id_ac69b5b4-1bf6-4e89-b332-699adaa3ca1c">WARNINGS</a></span><a href="#i4i_section_id_e85fd870-1187-4326-9b22-364a35ec4dd2"> 1a</a>. and <a href="#i4i_section_id_3fbeb069-b522-4e2e-a3d1-c22b9dfc7702">1d</a>.), changes in 
serum triglycerides and lipoprotein levels have been reported in oral 
contraceptive users.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>9. Elevated Blood Pressure<p>Women with significant <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should not be started on 
hormonal contraceptive. An increase in blood pressure has been reported in women 
taking oral contraceptives and this increase is more likely in older oral 
contraceptive users and with continued use. Data from the Royal College of 
General Practitioners and subsequent randomized trials have shown that the 
incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> increases with increasing concentrations of 
progestogens.</p>
<p>Women with a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>-related diseases, or 
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> should be encouraged to use another method of contraception. If 
women with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> elect to use oral contraceptives, they should be 
monitored closely, and if significant elevation of blood pressure occurs, oral 
contraceptives should be discontinued (see <span class="Bold"><a href="#i4i_contraindications_id_81c55af3-9c39-4f1a-a5c6-94d20e2d9729">CONTRAINDICATIONS</a></span> 
section). For most women, elevated blood pressure will return to normal after 
stopping oral contraceptives, and there is no difference in the occurrence of 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> among ever- and never-users.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>10. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><p>The onset or exacerbation of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or development of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> 
with a new pattern that is recurrent, persistent, or severe requires 
discontinuation of oral contraceptives and evaluation of the cause. (See <span class="Bold"><a href="#i4i_warnings_id_ac69b5b4-1bf6-4e89-b332-699adaa3ca1c">WARNINGS</a></span>, 
<a href="#i4i_section_id_358fc8b3-1e8c-4348-8680-6f8a3691d4c8">1c</a>.)</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>11. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities<p>When prescribing Jolessa<span class="Sup">™</span>, the convenience 
of fewer planned menses (4 per year instead of 13 per year) should be weighed 
against the inconvenience of increased <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span> and/or 
spotting.</p>
<p>The clinical trial (SEA 301) that compared the efficacy of Jolessa<span class="Sup">™</span> (91-day cycles) to an equivalent dosage 28-day cycle regimen 
also assessed <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span>. The participants in the study were 
composed primarily of women who had used oral contraceptives previously as 
opposed to new users. Women with a history of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/spotting ≥10 
consecutive days on oral contraceptives were excluded from the study. More 
Jolessa<span class="Sup">™</span> subjects, compared to subjects on the 28-day 
cycle regimen, discontinued prematurely for unacceptable <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (7.7% 
[Jolessa<span class="Sup">™</span>] vs. 1.8% [28-day cycle regimen]).</p>
<p>Table 4 shows the percentages of women with ≥ 7 days and ≥ 20 days of 
intermenstrual spotting and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the Jolessa<span class="Sup">™</span> 
and the 28-day cycle treatment groups.</p>
<a href="http://"></a><a name="ibd319517-a732-4106-8522-9bb566408a6c"></a><table width="486">
<caption><span>Table 4. Percentage of Subjects with <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">Intermenstrual Bleeding</span> and/or 
Spotting</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td>Days of 
<span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span> and/or spotting</td>
<td>Percentage of 
Subjects<a href="#footnote-13">*</a>
</td>
</tr>
<tr>
<td><span class="Bold">Jolessa™</span></td>
<td>Cycle 1 (N=385)</td>
<td>Cycle 4 (N=261)</td>
</tr>
<tr>
<td>≥ 7 days </td>
<td>65%</td>
<td>42%</td>
</tr>
<tr>
<td>≥ 20 days </td>
<td>35%</td>
<td>15%</td>
</tr>
<tr>
<td><span class="Bold">28-day 
regimen </span></td>
<td>Cycles 1-4 (N=194)</td>
<td>Cycles 10-13 (N=158)</td>
</tr>
<tr>
<td>≥ 7 days </td>
<td>38%</td>
<td>39%</td>
</tr>
<tr class="Last">
<td>≥ 20 days </td>
<td>6%</td>
<td>4%</td>
</tr>
</tbody>
</table>
<a href="#footnote-reference-13">*</a>Based on spotting and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on days 1-84 of a 91 day cycle in the 
Jolessa<span class="Sup">™</span> subjects and days 1-21 of a 28 day cycle over 4 
cycles in the 28-day dosing regimen<br><p>Total days of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting (withdrawal plus intermenstrual) were 
similar over one year of treatment for Jolessa™ subjects and subjects on the 
28-day cycle regimen.</p>
<p>As in any case of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> irregularities, nonhormonal causes should always 
be considered and adequate diagnostic measures taken to rule out malignancy or 
pregnancy.</p>
<p>In the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, pregnancy should be ruled out. Some women may 
encounter post-pill <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span> (possibly with <span class="product-label-link" type="condition" conceptid="4144685" conceptname="Anovulation">anovulation</span>), 
especially when such a condition was preexistent.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>1. <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Diseases</span><p class="First"><span class="Bold">Patients should be counseled that this product 
does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other sexually transmitted 
diseases.</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>2. Physical Examination and Follow-up<p>A periodic history and physical examination are appropriate for 
all women, including women using oral contraceptives. The physical examination, 
however, may be deferred until after initiation of oral contraceptives if 
requested by the woman and judged appropriate by the clinician. The physical 
examination should include special reference to blood pressure, breasts, abdomen 
and pelvic organs, including cervical <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span>, and relevant laboratory tests. 
In the case of undiagnosed, persistent or recurrent abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, 
appropriate diagnostic measures should be conducted to rule out malignancy. 
Women with a strong family history of breast cancer or who have breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> 
should be monitored with particular care.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>3. Lipid Disorders<p>Women who are being treated for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> should be 
followed closely if they elect to use oral contraceptives.</p>
<p>Some progestogens may elevate LDL levels and may render the control of 
<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> more difficult. (See <span class="Bold"><a href="#i4i_warnings_id_ac69b5b4-1bf6-4e89-b332-699adaa3ca1c">WARNINGS 
</a></span><a href="#i4i_section_id_3fbeb069-b522-4e2e-a3d1-c22b9dfc7702">1d.</a>)</p>
<p>In patients with familial defects of lipoprotein metabolism receiving 
estrogen-containing preparations, there have been case reports of significant 
elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>4. Liver Function<p>If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops in any woman receiving such drugs, the 
medication should be discontinued. Steroid hormones may be poorly metabolized in 
patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>5. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span><p>Oral contraceptives may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. 
They should be prescribed with caution, and only with careful monitoring, in 
patients with conditions which might be aggravated by <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>6. <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">Emotional Disorders</span><p>Women with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed 
and the drug discontinued if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree. Patients 
becoming significantly depressed while taking oral contraceptives should stop 
the medication and use an alternate method of contraception in an attempt to 
determine whether the symptom is drug related.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7. Contact Lenses<p>Contact-lens wearers who develop visual changes or changes in 
lens tolerance should be assessed by an ophthalmologist.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>8. Drug Interactions<p><span class="Bold">Changes in contraceptive effectiveness 
associated with co-administration of other products</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">a. Anti-infective agents and 
anticonvulsants</span><p>Contraceptive effectiveness may be reduced when hormonal 
contraceptives are co-administered with antibiotics, anticonvulsants, and other 
drugs that increase the metabolism of contraceptive steroids. This could result 
in <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Examples include rifampin, 
barbiturates, phenylbutazone, phenytoin, carbamazepine, felbamate, 
oxcarbazepine, topiramate, and griseofulvin. Several cases of contraceptive 
failure and breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported in the literature with 
concomitant administration of antibiotics such as ampicillin and tetracyclines. 
However, clinical pharmacology studies investigating drug interaction between 
combined oral contraceptives and these antibiotics have reported inconsistent 
results.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">b. Anti-HIV protease 
inhibitors</span><p>Several of the anti-HIV protease inhibitors have been studied 
with co-administration of combination oral contraceptives; significant changes 
(increase and decrease) in the plasma levels of the estrogen and progestin have 
been noted in some cases. The safety and efficacy of combination oral 
contraceptive products may be affected with co-administration of anti-HIV 
protease inhibitors. Healthcare providers should refer to the label of the 
individual anti-HIV protease inhibitors for further drug-drug interaction 
information.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">c. Herbal products</span><p>Herbal products containing St. John’s Wort (hypericum perforatum) 
may induce hepatic enzymes (cytochrome P450) and p-glycoprotein transporter and 
may reduce the effectiveness of contraceptive steroids. This may also result in 
breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p><span class="Bold">Increase in plasma levels of estradiol associated with 
co-administered drugs</span></p>
<p>Co-administration of atorvastatin and certain combination oral contraceptives 
containing ethinyl estradiol increase AUC values for ethinyl estradiol by 
approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl 
estradiol levels, possibly by inhibition of conjugation. CYP 3A4 inhibitors such 
as itraconazole or ketoconazole may increase plasma hormone levels.</p>
<p><span class="Bold">Changes in plasma levels of co-administered drugs</span></p>
<p>Combination oral contraceptives containing some synthetic estrogens (e.g., 
ethinyl estradiol) may inhibit the metabolism of other compounds. Increased 
plasma concentrations of cyclosporin, prednisolone, and theophylline have been 
reported with concomitant administration of combination oral contraceptives. 
Decreased plasma concentrations of acetaminophen and increased clearance of 
temazepam, salicylic acid, morphine and clofibric acid, due to induction of 
conjugation have been noted when these drugs were administered with combination 
oral contraceptives. Combination OCs have been shown to significantly decrease 
plasma concentrations of lamotrigine likely due to induction of lamotrigine 
glucuronidation. This may reduce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control; therefore, dosage adjustments 
of lamotrigine may be necessary. Consult the labeling of the concurrently-used 
drug to obtain further information about interactions with COCs or the potential 
for enzyme alterations.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>9. Interactions with Laboratory Tests<p>Certain endocrine and liver function tests and blood components 
may be affected by oral contraceptives:</p> a. Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> and factors VII, VIII, IX, and X; decreased 
antithrombin 3; increased norepinephrine-induced platelet aggregability. b. Increased thyroid-binding globulin (TBG) leading to increased circulating 
total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column 
or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the 
elevated TBG, free T4 concentration is unaltered. c. Other binding proteins may be elevated in serum. d. <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">Sex hormone binding globulins</span> are increased and result in elevated levels 
of total circulating sex steroids and corticoids; however, free or biologically 
active levels remain unchanged. e. Triglycerides may be increased and levels of various other lipids and 
lipoproteins may be affected. f. Glucose tolerance may be decreased. g. Serum folate levels may be depressed by oral contraceptive therapy. This 
may be of clinical significance if a woman becomes pregnant shortly after 
discontinuing oral contraceptives.<a href="http://"></a><a href="http://"></a><a href="http://"></a>10. Carcinogenesis<p>See <span class="Bold"><a href="#i4i_warnings_id_ac69b5b4-1bf6-4e89-b332-699adaa3ca1c">WARNINGS</a></span> 
section.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>11. Pregnancy<p>Pregnancy Category X. See <span class="Bold"><a href="#i4i_contraindications_id_81c55af3-9c39-4f1a-a5c6-94d20e2d9729">CONTRAINDICATIONS</a></span> 
and <span class="Bold"><a href="#i4i_warnings_id_ac69b5b4-1bf6-4e89-b332-699adaa3ca1c">WARNINGS</a></span> 
sections.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>12. Nursing Mothers<p>Small amounts of oral contraceptive steroids and/or metabolites 
have been identified in the milk of nursing mothers, and a few adverse effects 
on the child have been reported, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In 
addition, oral contraceptives given in the postpartum period may interfere with 
lactation by decreasing the quantity and quality of breast milk. If possible, 
the nursing mother should be advised not to use oral contraceptives but to use 
other forms of contraception until she has completely weaned her child.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>13. Pediatric Use<p>Safety and efficacy of Jolessa<span class="Sup">™</span> tablets 
have been established in women of reproductive age. Safety and efficacy are 
expected to be the same in postpubertal adolescents under the age of 16 and 
users 16 and older. Use of Jolessa<span class="Sup">™</span> before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is 
not indicated.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>14. Geriatric Use<p>Jolessa<span class="Sup">™</span> tablets have not been studied in 
women who have reached <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9"></a><p></p>
<h1>INFORMATION FOR PATIENT</h1>
<p class="First">See <a href="#i4i_patient_package_insert_id_bb409847-a3b7-467f-823a-d3e5a5f0ae8e">Patient 
Labeling</a> Printed Below.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">An increased risk of the following serious adverse reactions has 
been associated with the use of oral contraceptives (see <span class="Bold"><a href="#i4i_warnings_id_ac69b5b4-1bf6-4e89-b332-699adaa3ca1c">WARNINGS</a></span> 
section):</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span></li>
<li>Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span></li>
<li><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span></li>
<li><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span></li>
<li><span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">Cerebral thrombosis</span></li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></li>
<li><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span></li>
</ul>
<p>There is evidence of an association between the following conditions and the 
use of oral contraceptives:</p>
<ul>
<li>Mesenteric <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></li>
<li>Retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></li>
</ul>
<p>The following adverse reactions have been reported in patients receiving oral 
contraceptives and are believed to be drug related:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> (such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>)</li>
<li>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>Spotting</li>
<li>Change in menstrual flow</li>
<li><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></li>
<li>Temporary <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> after discontinuation of treatment</li>
<li><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>/<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span></li>
<li><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span>/<span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span> which may persist</li>
<li>Breast changes: <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, enlargement, and secretion</li>
<li>Change in weight or appetite (increase or decrease)</li>
<li>Change in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span> and secretion</li>
<li>Possible diminution in lactation when given immediately postpartum</li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span></li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (allergic)</li>
<li><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood changes</span>, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span></li>
<li>Change in corneal curvature (steepening)</li>
<li>Intolerance to contact lenses</li>
<li>Decrease in serum folate levels</li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span></li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span></li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span></li>
<li>Aggravation of <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span></li>
<li>Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and 
severe reactions with respiratory and circulatory symptoms</li>
</ul>
<p>The following adverse reactions have been reported in users of oral 
contraceptives and the association has been neither confirmed nor refuted:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="439081" conceptname="Premenstrual tension syndrome">Premenstrual syndrome</span></li>
<li><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></li>
<li><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span> which may lead to partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>-like syndrome</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></li>
<li>Loss of scalp hair</li>
<li><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span></li>
<li><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema nodosum</span></li>
<li>Hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span></li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></li>
<li><span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic uremic syndrome</span></li>
<li>Budd-Chiari syndrome</li>
<li><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></li>
<li>Changes in libido</li>
<li><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute 
ingestion of large doses of oral contraceptives by young children.</p>
<p>Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in 
females.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>NONCONTRACEPTIVE HEALTH BENEFITS</h1>
<p class="First">The following noncontraceptive health benefits related to the use 
of oral contraceptives are supported by epidemiological studies which largely 
utilized oral contraceptive formulations containing doses exceeding 0.035 mg of 
ethinyl estradiol or 0.05 mg of mestranol.</p>
<p>Effects on menses:</p>
<ul>
<li>May decrease blood loss and may decrease incidence of iron-deficiency 
<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></li>
<li>May decrease incidence of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span></li>
</ul>
<p>Effects related to inhibition of ovulation:</p>
<ul>
<li>May decrease incidence of functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span></li>
<li>May decrease incidence of ectopic pregnancies</li>
</ul>
<p>Effects from long-term use:</p>
<ul>
<li>May decrease incidence of fibroadenomas and fibrocystic disease of the 
breast</li>
<li>May decrease incidence of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span></li>
<li>May decrease incidence of endometrial cancer</li>
<li>May decrease incidence of ovarian cancer</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-13"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Although the occurrence of pregnancy is unlikely if Jolessa<span class="Sup">™</span> is taken according to directions, if <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> does 
not occur while taking white (inactive) tablets, the possibility of pregnancy 
must be considered. Appropriate diagnostic measures to rule out pregnancy should 
be taken at the time of any missed menstrual period. Jolessa<span class="Sup">™</span> should be discontinued if pregnancy is confirmed.</p>
<p>The dosage of Jolessa<span class="Sup">™</span> is one pink (active) tablet 
daily for 84 consecutive days, followed by 7 days of white (inert) tablets. To 
achieve maximum contraceptive effectiveness, Jolessa<span class="Sup">™</span> 
must be taken exactly as directed and at intervals not exceeding 24 hours. 
Ideally, the tablets should be taken at the same time of the day on each day of 
active treatment. The tablets should not be removed from the protective <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> 
packaging to avoid damage to the product. The dispenser card should be kept in 
the foil pouch until dispensed to the patient.</p>
<p>During the first cycle of medication, the patient is instructed to begin 
taking Jolessa<span class="Sup">™</span> on the first Sunday after the onset of 
menstruation. If menstruation begins on a Sunday, the first tablet (pink) is 
taken that day. One pink tablet should be taken daily for 84 consecutive days, 
followed by 7 days on which a white (inert) tablet is taken. <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">Withdrawal bleeding</span> 
should occur during the 7 days following discontinuation of pink active tablets. 
During the first cycle, contraceptive reliance should not be placed on 
Jolessa<span class="Sup">™</span> until a pink (active) tablet has been taken 
daily for 7 consecutive days and a non-hormonal back-up method of birth control 
(such as condoms or spermicide) should be used during those 7 days. The 
possibility of ovulation and conception prior to initiation of medication should 
be considered.</p>
<p>The patient begins her next and all subsequent 91-day courses of tablets 
without interruption on the same day of the week (Sunday) on which she began her 
first course, following the same schedule: 84 days on which pink tablets are 
taken followed by 7 days on which white tablets are taken. If in any cycle the 
patient starts tablets later than the proper day, she should protect herself 
against pregnancy by using a non-hormonal back-up method of birth control until 
she has taken a pink tablet daily for 7 consecutive days.</p>
<p>If spotting or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs, the patient is instructed to 
continue on the same regimen. This type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be transient and without 
significance; however, if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is persistent or prolonged, the patient 
is advised to consult her healthcare provider.</p>
<p>For patient instructions regarding missed pills, see the “<span class="Bold">WHAT TO DO IF YOU MISS PILLS</span>? section in the <span class="Bold"><a href="#i4i_patient_package_insert_id_36021c95-3d8c-40eb-b827-7d79e6d5ad65">DETAILED 
PATIENT LABELING</a></span>. Any time the patient misses two or more pink 
tablets, she should also use another method of nonhormonal back-up contraception 
until she has taken a pink tablet daily for seven consecutive days. If the 
patient misses one or more white tablets, she is still protected against 
pregnancy provided she begins taking pink tablets again on the proper day. The 
possibility of ovulation increases with each successive day that scheduled pink 
tablets are missed. The risk of pregnancy increases with each active (pink) 
tablet missed.</p>
<p>In the nonlactating mother, Jolessa™ may be initiated no earlier than day 28 
postpartum, for contraception due to the increased risk for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>. 
When the tablets are administered in the postpartum period, the increased risk 
of thromboembolic disease associated with the postpartum period must be 
considered (See <span class="Bold"><a href="#i4i_contraindications_id_81c55af3-9c39-4f1a-a5c6-94d20e2d9729">CONTRAINDICATIONS</a></span>, 
<span class="Bold"><a href="#i4i_warnings_id_ac69b5b4-1bf6-4e89-b332-699adaa3ca1c">WARNINGS</a></span> 
and <span class="Bold"><a href="#i4i_precautions_id_4c71e74e-f3c2-4f5c-83b2-b016d0f3d093">PRECAUTIONS</a></span> 
concerning thromboembolic disease). The patient should be advised to use a 
nonhormonal back-up method for the first 7 days of tablet-taking. However, if 
intercourse has already occurred, the possibility of ovulation and conception 
prior to initiation of medication should be considered. Jolessa™ may be 
initiated immediately after a first-trimester abortion; if the patient starts 
Jolessa™ immediately, additional contraceptive measures are not needed.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Jolessa™ tablets (levonorgestrel / ethinyl estradiol tablets) 
0.15 mg / 0.03 mg are available in Extended-Cycle Tablet Dispensers, each 
containing a 13-week supply of tablets: 84 pink tablets, each containing 0.15 mg 
of levonorgestrel and 0.03 mg ethinyl estradiol, and 7 white inert tablets. The 
active pink tablets are round, film-coated, unscored, debossed with <span class="Bold">stylized </span><span class="Bold">b</span> on one side and <span class="Bold">992 </span>on the other side. The white inert tablets are round, 
unscored, debossed with <span class="Bold">stylized </span><span class="Bold">b</span> on one side and <span class="Bold">208 </span>on the other 
side.</p>
<a name="ib73e038f-e8c7-47f6-81be-03096d3ff868"></a><table width="50%"><tbody class="Headless"><tr class="First Last">
<td>Available in dispenser of 91 tablets<br>
</td>
<td>NDC 54868-6044-0<br>
</td>
</tr></tbody></table>
<a href="http://"></a><p>Store at 20° to 25° C (68° to 77° F) [See USP Controlled Room 
Temperature].</p>
<p>References available upon request.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-15"></a><p></p>
<h1>BRIEF SUMMARY PATIENT PACKAGE INSERT</h1>
<p class="First"><span class="Bold">This product (like all oral contraceptives) is 
intended to prevent pregnancy. It does not protect against HIV 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span><span class="Bold"> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> 
such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and 
<span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</span></p>
<p>Oral contraceptives, also known as “birth control pills? or “the pill?, are 
taken to prevent pregnancy, and when taken correctly, have a failure rate of 
approximately 1.0% per year (1 pregnancy per 100 women per year of use). The 
typical failure rate of pill users is approximately 5% per year when women who 
miss pills are included.</p>
<p>For the majority of women, oral contraceptives can be taken safely. But for 
some women oral contraceptive use is associated with certain serious diseases 
that can be life threatening or may cause temporary or permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The risks associated with taking oral contraceptives increase 
significantly if you:</p>
<ul>
<li>smoke</li>
<li>have high blood pressure, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or are obese</li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, 
cancer of the breast or sex organs, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or malignant or benign liver 
tumors</li>
</ul>
<p>You should not take the pill if you are pregnant.</p>
<p>Although cardiovascular disease risks may be increased with oral 
contraceptive use after age 40 in healthy, non-smoking women (even with the 
newer low-dose formulations), there are also greater potential health risks 
associated with pregnancy in older women.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">Cigarette smoking increases the risk of serious 
cardiovascular side effects from oral contraceptive use. This risk increases 
with age and with the amount of smoking (15 or more cigarettes per day has been 
associated with a significantly increased risk) and is quite marked in women 
over 35 years of age. Women who use oral contraceptives should not smoke.</span></p>
<a href="http://"></a><a href="http://"></a><p>Most side effects of the pill are not serious. The most common 
are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting between menstrual periods, weight 
gain, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, and difficulty wearing contact lenses. Some of these 
side effects, especially <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, may subside within the first 3 
months of use.</p>
<p>The serious side effects of the pill occur very infrequently, especially if 
you are in good health and do not smoke. However, you should know that the 
following medical conditions have been associated with or made worse by the 
pill:</p>
<ol>
<li>Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), 
stoppage or rupture of a blood vessel in the brain (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>), blockage of blood 
vessels in the heart (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>) or other organs of the 
body. As mentioned above, smoking increases the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and subsequent serious medical consequences. Women with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> also 
may be at increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> when taking the pill.</li>
<li><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, which may rupture and cause severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. A possible but 
not definite association has been found with the pill and liver cancer. However, 
liver cancers are extremely rare. The chance of developing liver cancer from 
using the pill is thus even rarer.</li>
<li>High blood pressure, although blood pressure usually returns to normal when 
the pill is stopped.</li>
</ol>
<p>The symptoms associated with these serious side effects are discussed in the 
detailed patient information leaflet. Notify your healthcare provider if you 
notice any unusual physical disturbances while taking the pill. In addition, 
drugs such as rifampin, as well as some anticonvulsants and some antibiotics, 
and herbal preparations containing St. John’s Wort (hypericum perforatum) may 
decrease oral contraceptive effectiveness.</p>
<p>Breast cancer has been diagnosed slightly more often in women who use the 
pill than in women of the same age who do not use the pill. This very small 
increase in the number of breast cancer diagnoses gradually disappears during 
the 10 years after stopping use of the pill. It is not known whether the 
difference is caused by the pill. It maybe that women taking the pill were 
examined more often, so that breast cancer was more likely to be detected. You 
should have regular breast examinations by a healthcare provider and examine 
your own breasts monthly. Tell your healthcare provider if you have a family 
history of breast cancer or if you have had breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or an abnormal 
mammogram. Women who currently have or have had breast cancer should not use 
hormonal contraceptives because breast cancer is usually a hormone-sensitive 
tumor.</p>
<p>Some studies have found an increase in the incidence of cancer or 
precancerous lesions of the cervix in women who use the pill. However, this 
finding may be related to factors other than the use of the pill.</p>
<p>Be sure to discuss any medical condition you may have with your healthcare 
provider. Your healthcare provider will take a medical and family history before 
prescribing oral contraceptives and will examine you. The physical examination 
may be delayed to another time if you request it and the healthcare provider 
believes that it is appropriate to postpone it. You should be reexamined at 
least once a year while taking oral contraceptives. The detailed patient 
information leaflet gives you further information which you should read and 
discuss with your healthcare provider.</p>
<p><span class="Bold">What You Should Know About Your Menstrual Cycle When Taking 
Jolessa<span class="Sup">™</span></span></p>
<p>When you take Jolessa<span class="Sup">™</span>, which has a 91-day treatment 
cycle, you should expect to have 4 menstrual periods per year (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when you 
are taking the 7 white pills). However, you also should expect to have more 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting between your menstrual periods than if you were taking an 
oral contraceptive with a 28-day treatment cycle. During the first Jolessa<span class="Sup">™</span> treatment cycle, about 1 in 3 women may have 20 or more days 
of unplanned <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when you are taking pink pills). 
This <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting tends to decrease during later cycles. Do not stop 
Jolessa<span class="Sup">™</span> because of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If the spotting 
continues for more than 7 consecutive days or if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is heavy, call 
your healthcare provider.</p>
<p><span class="Bold">If You Miss Your Menstrual Period When Taking Jolessa<span class="Sup">™</span></span></p>
<p>You should consider the possibility that you are pregnant if you miss your 
menstrual period (no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on the days that you are taking white tablets). 
Since scheduled menstrual periods are less frequent when you are taking 
Jolessa<span class="Sup">™</span>, notify your healthcare provider that you have 
missed your period and are taking Jolessa<span class="Sup">™</span>. Also notify 
your healthcare provider if you have symptoms of pregnancy such as morning 
sickness or unusual <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>. It is important that your healthcare 
provider evaluates you to determine if you are pregnant. Stop taking 
Jolessa<span class="Sup">™</span> if it is determined that you are pregnant.</p>
<p><span class="Bold">HOW TO TAKE JOLESSA<span class="Sup">™</span></span></p>
<p><span class="Bold">IMPORTANT POINTS TO REMEMBER <span class="Italics">BEFORE</span> YOU START TAKING JOLESSA<span class="Sup">™</span></span></p>
<ol>
<li>BE SURE TO READ THESE DIRECTIONS:<br>• Before you start taking your 
pills.<br>• Anytime you are not sure what to do.</li>
<li>THE RIGHT WAY TO TAKE JOLESSA™ IS TO TAKE ONE PILL EVERY DAY AT THE SAME 
TIME.<br>If you miss pills you could get pregnant. This includes starting the 
pack late. The more pills you miss, the more likely you are to get 
pregnant.</li>
<li>MANY WOMEN MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST FEW WEEKS OF 
TAKING PILLS.<br>If you feel sick to your stomach, do not stop taking the pill. 
The problem will usually go away. If it doesn’t go away, check with your 
healthcare provider.</li>
<li>MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> DURING THE FIRST FEW MONTHS OF 
TAKING JOLESSA™. <span class="Bold">Do not stop taking your pills even if you are 
having irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span>. If the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> lasts for more than 7 
consecutive days, talk to your healthcare provider.</li>
<li>MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make 
up these missed pills.<br>On the days you take 2 pills to make up for missed 
pills, you could also feel a little sick to your stomach.</li>
<li>IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, or IF YOU TAKE SOME MEDICINES, including 
some antibiotics and the herbal supplement St. John’s Wort, Jolessa™ may not 
work as well. Use a back-up method (such as condoms or spermicides) until you 
check with your healthcare provider.</li>
<li>IF YOU HAVE TROUBLE REMEMBERING TO TAKE JOLESSA™, talk to your healthcare 
provider about how to make pill-taking easier or about using another method of 
birth control.</li>
<li>IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS 
LEAFLET, call your healthcare provider.</li>
</ol>
<p><span class="Bold"><span class="Italics">BEFORE</span> YOU START TAKING 
JOLESSA<span class="Sup">™</span></span></p>
<ol>
<li>DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take 
it at about the same time every day.</li>
<li>LOOK AT YOUR EXTENDED-CYCLE TABLET DISPENSER. Your Tablet Dispenser consists 
of 3 trays with cards that hold 91 individually sealed pills (a 13-week or 
91-day cycle). The 91 pills consist of 84 pink pills (active pills with 
hormones) and 7 white pills, (inactive pills without hormone). Trays 1 and 2 
each contain 28 pink pills (4 rows of 7 pills). Tray 3 contains 35 pills 
consisting of 28 pinks pills (4 rows of 7 pills) and 7 white pills (1 row of 7 
pills).  <div class="Figure"><img alt="image of dispenser" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=709031e4-4c20-4ea7-beff-6c459709a433&amp;name=dispenser.jpg"></div>
</li>
<li>ALSO FIND:<br>• Where on the first row in the pack to start taking pills 
(upper left corner at the start arrow) and<br>• In what order to take the pills 
(follow the weeks and arrow).</li>
<li>BE SURE YOU HAVE READY AT ALL TIMES ANOTHER KIND OF BIRTH CONTROL (such as 
condoms or spermicides), to use as a back-up in case you miss pills.</li>
</ol>
<p><span class="Bold">WHEN TO START JOLESSA<span class="Sup">™</span></span></p>
<ol>
<li>Take the first “active? pink pill on the <span class="Italics">Sunday after 
your period starts</span>, even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins 
on Sunday, start the first pink pill that same day.</li>
<li>
<span class="Italics">Use another method of birth control (such as condom or 
spermicide)</span> as a back-up method if you have sex anytime from the Sunday 
you start your first pink pill until the next Sunday (first 7 days).</li>
</ol>
<br><p><span class="Bold">HOW TO TAKE JOLESSA<span class="Sup">™</span></span></p>
<ol>
<li>Take one pill at the same time every day until you have taken the last pill 
in the tablet dispenser.<br>Do not skip pills even if you are spotting or 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).<br>Do not skip pills even if you 
do not have sex very often.</li>
<li>WHEN YOU FINISH A TABLET DISPENSER.<br>After taking the last white pill, 
start taking the first pink pill from a new Extended-Cycle Tablet Dispenser the 
very next day regardless of when your period started. This should be on a 
Sunday.</li>
<li>If you miss your period when you are taking the white pills, call your 
healthcare provider because you may be pregnant.</li>
</ol>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1 </span>pink “active? pill:</p>
<ol>
<li>Take it as soon as you remember. Take the next pill at your regular time. 
This means you may take 2 pills in 1 day.</li>
<li>You do not need to use a back-up birth control method if you have 
sex.</li>
</ol>
<p>If you <span class="Bold">MISS 2 </span>pink “active? pills in a row:</p>
<ol>
<li>Take 2 pills on the day you remember, and 2 pills the next day.</li>
<li>Then take 1 pill a day until you finish the pack.</li>
<li>You COULD BECOME PREGNANT if you have sex in the 7 days after you restart 
your pills. You MUST use another birth control method (such as condoms or 
spermicide) as a back-up on the 7 days after you restart your pills.</li>
</ol>
<p>If you <span class="Bold">MISS 3 OR MORE </span>pink “active? pills in a 
row:</p>
<ol>
<li>Do not remove the missed pills from the pack as they will not be taken. Keep 
taking 1 pill every day as indicated on the pack until you have completed all of 
the remaining pills in the pack. For example: If you resume taking the pill on 
Thursday, take the pill under “Thursday? and do not take the missed pills. You 
may experience <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during the week following the missed pills.</li>
<li>You COULD BECOME PREGNANT if you have sex during the days of missed pills or 
during the first 7 days after restarting your pills.</li>
<li>You <span class="Bold">must </span>use a non-hormonal birth control method 
(such as condoms or spermicide) as a back-up when you miss pills and for the 
first 7 days after you restart your pills. <span class="Bold">If you miss your 
period when taking the white pills, call your healthcare provider because you 
may be pregnant</span>.</li>
</ol>
<p>If you <span class="Bold">MISS ANY </span>of the 7 white inactive pills.</p>
<ol>
<li>Throw away the missed pills.</li>
<li>Keep taking the scheduled pills until the pack is finished.</li>
<li>You do not need a back-up method of birth control.</li>
</ol>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE 
PILLS YOU HAVE MISSED</span></p>
<ol>
<li>Use a BACK-UP METHOD anytime you have sex.</li>
<li>KEEP TAKING ONE PILL EACH DAY until you contact your healthcare 
provider.</li>
</ol>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>DETAILED PATIENT LABELING<p><span class="Bold">This product (like all oral contraceptives) is 
intended to prevent pregnancy. Oral contraceptives do not protect against 
transmission of HIV (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> such as 
chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and 
<span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</span></p>
<p><span class="Bold">INTRODUCTION</span></p>
<p>Any woman who considers using oral contraceptives (“the birth control pill? 
or “the pill?) should understand the benefits and risks of using this form of 
birth control. Although oral contraceptives have important advantages over other 
methods of contraception, they have certain risks that no other method has, and 
some of these risks may continue after you have stopped using the oral 
contraceptive. This leaflet will give you much of the information you will need 
to make this decision and will also help you determine if you are at risk of 
developing any of the serious side effects of the pill. It will tell you how to 
use Jolessa<span class="Sup">™</span> properly so that it will be as effective as 
possible. However, this leaflet is not a replacement for a careful discussion 
between you and your healthcare provider. You should discuss the information 
provided in this leaflet with your healthcare provider, both when you first 
start taking Jolessa<span class="Sup">™</span> and during your revisits. You 
should also follow your healthcare provider's advice with regard to regular 
check-ups while you are on Jolessa<span class="Sup">™</span>.</p>
<p><span class="Bold">EFFECTIVENESS OF ORAL CONTRACEPTIVES</span></p>
<p>Oral contraceptives or “the birth control pill? or “the pill? are used to 
prevent pregnancy and are more effective than most other nonsurgical methods of 
birth control. The chance of becoming pregnant is approximately 1.0% per year (1 
pregnancy per 100 women per year of use) when the pills are used correctly, and 
no pills are missed. Typical failure rates are approximately 5.0% per year when 
women who miss pills are included. The chance of becoming pregnant increases 
with each missed pill during the menstrual cycle.</p>
<p>In comparison, typical failure rates for other methods of birth control 
during the first year of use are as follows:</p>
<p>No methods: 85%</p>
<p>Vaginal sponge: 20 to 40%</p>
<p>Cervical cap: 20 to 40%</p>
<p>Spermicides alone: 26%</p>
<p>Periodic abstinence: 25%</p>
<p>Condom (female): 21%</p>
<p>Diaphragm with spermicides: 20%</p>
<p>Withdrawal: 19%</p>
<p>Condom (male): 14%</p>
<p>Female sterilization: 0.5%</p>
<p>IUD: 0.1 to 2.0%</p>
<p>Injectable progestogen: 0.3%</p>
<p>Male sterilization: 0.15%</p>
<p>Norplant system: 0.05%</p>
<p><span class="Bold">WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES</span></p>
<p> </p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">Cigarette smoking increases the risk of serious 
cardiovascular side effects from oral contraceptive use. This risk increases 
with age and with the amount of smoking (15 or more cigarettes per day has been 
associated with a significantly increased risk) and is quite marked in women 
over 35 years of age. Women who use oral contraceptives should not smoke.</span></p>
<a href="http://"></a><a href="http://"></a><p> Some women should not use the pill. You should not use the pill 
if you have any of the following conditions:</p>
<ul>
<li>A history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>A history of blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (pulmonary 
<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>), or eyes</li>
<li>A history of blood clots in the deep veins of your legs</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>)</li>
<li>Known or suspected breast cancer or cancer of the lining of the uterus, 
cervix, vagina, or certain hormonally-sensitive cancers</li>
<li>Unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> (until a diagnosis is reached by your 
healthcare provider)</li>
<li>Yellowing of the whites of the eyes or of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) during 
pregnancy or during previous use of the pill</li>
<li><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumor</span> (benign or cancerous)</li>
<li>Known or suspected pregnancy</li>
<li>Heart valve or heart rhythm disorders that may be associated with formation 
of blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> affecting your circulation</li>
<li>Uncontrolled high blood pressure</li>
<li>Active liver disease with <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span></li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of Jolessa<span class="Sup">™</span>
</li>
<li>A need for surgery with prolonged bedrest</li>
</ul>
<p>Tell your healthcare provider if you have any of the above conditions. Your 
healthcare provider can recommend a safer method of birth control.</p>
<p><span class="Bold">OTHER CONSIDERATIONS BEFORE TAKING ORAL 
CONTRACEPTIVES</span></p>
<p>Tell your healthcare provider if you or any family member has ever had:</p>
<ul>
<li>Breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, fibrocystic disease of the breast, an abnormal breast X-ray 
or mammogram</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></li>
<li>Elevated <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides</li>
<li>High blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> or other <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span></li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></li>
<li>Gallbladder, liver, heart or kidney disease</li>
<li>History of scanty or irregular menstrual periods</li>
</ul>
<p>Women with any of these conditions should be checked often by their 
healthcare provider if they choose to use oral contraceptives. Also, be sure to 
inform your healthcare provider if you smoke or are on any medications.</p>
<p><span class="Bold">RISKS OF TAKING ORAL CONTRACEPTIVES</span></p>
<p>If you use Jolessa<span class="Sup">™</span> you will receive more exposure to 
hormones on a yearly basis than if you used a conventional 28-day cycle oral 
contraceptives containing a similar amount of estrogen and progestin (an 
additional 9 weeks exposure per year). While this added exposure may pose an 
additional risk of thrombotic and thromboembolic disease, studies to date with 
Jolessa™ have not suggested an increased risk of these disorders.</p>
<p>1. <span class="Bold">Risk of Developing Blood Clots</span></p>
<p>Blood clots and blockage of blood vessels are the most serious side effects 
of taking oral contraceptives and can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. In 
particular, a clot in the legs can cause <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> and a clot that 
travels to the lungs can cause a sudden blocking of the vessel carrying blood to 
the lungs. Rarely, clots occur in the blood vessels of the eye and may cause 
<span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, or impaired vision.</p>
<p>If you take oral contraceptives and need elective surgery, need to stay in 
bed for a prolonged illness, or have recently delivered a baby, you may be at 
risk of developing blood clots. You should consult your healthcare provider 
about stopping oral contraceptives three to four weeks before surgery and not 
taking oral contraceptives for two weeks after surgery or during bed rest. You 
should also not take oral contraceptives soon after delivery of a baby. It is 
advisable to wait for at least four weeks after delivery if you are not 
breastfeeding. If you are breastfeeding, you should wait until you have weaned 
your child before using the pill (See also the section on <span class="Bold">Breastfeeding </span>in “<span class="Bold">GENERAL 
PRECAUTIONS</span>.?)</p>
<p>The risk of circulatory disease in oral contraceptive users may be higher in 
users of high-dose pills (containing 50 micrograms or higher of ethinyl 
estradiol) and may be greater with longer duration of oral contraceptive use. In 
addition, some of these increased risks may continue for a number of years after 
stopping oral contraceptives. The risk of abnormal blood clotting increases with 
age in both users and nonusers of oral contraceptives, but the increased risk 
from the oral contraceptive appears to be present at all ages. For women aged 20 
to 44, it is estimated that about 1 in 2,000 using oral contraceptives will be 
hospitalized each year because of abnormal clotting.</p>
<p>Among nonusers in the same age group, about 1 in 20,000 would be hospitalized 
each year. For oral contraceptive users in general, it has been estimated that 
in women between the ages of 15 and 34 the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to a circulatory 
disorder is about 1 in 12,000 per year, whereas for nonusers the rate is about 1 
in 50,000 per year. In the age group 35 to 44, the risk is estimated to be about 
1 in 2,500 per year for oral contraceptive users and about 1 in 10,000 per year 
for nonusers.</p>
<p>2. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart Attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Strokes</span></span></p>
<p>Oral contraceptives may increase the tendency to develop <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> (stoppage or 
rupture of blood vessels in the brain) and <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> 
(blockage of blood vessels in the heart). Any of these conditions can cause 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</p>
<p>Smoking greatly increases the possibility of suffering <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>. Furthermore, smoking and the use of oral contraceptives greatly 
increase the chances of developing and dying of heart disease.</p>
<p>Women with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (especially <span class="product-label-link" type="condition" conceptid="381549" conceptname="Migraine with aura">migraine with aura</span>) who take oral 
contraceptives also may be at higher risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>3. <span class="Bold"><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></span></p>
<p>Oral contraceptive users probably have a greater risk than nonusers of having 
<span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, although this risk may be related to pills containing high 
doses of estrogens.</p>
<p>4. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver Tumors</span></span></p>
<p>In rare cases, oral contraceptives can cause benign but dangerous liver 
tumors. These benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> can rupture and cause fatal internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. 
In addition, a possible but not definite association has been found with the 
pill and liver cancers in two studies in which a few women who developed these 
very rare cancers were found to have used oral contraceptives for long periods. 
However, liver cancers in general are extremely rare and the chance of 
developing liver cancer from using the pill is thus even rarer.</p>
<p>5. <span class="Bold">Cancer of the Breast and Reproductive Organs</span></p>
<p>Breast cancer has been diagnosed slightly more often in women who use the 
pill than in women of the same age who do not use the pill. This small increase 
in the number of breast cancer diagnoses gradually disappears during the 10 
years after stopping use of the pill. It is not known whether the difference is 
caused by the pill. It may be that women taking the pill are examined more 
often, so that breast cancer is more likely to be detected. You should have 
regular breast examinations by a healthcare provider and examine your own 
breasts monthly. Tell your healthcare provider if you have a family history of 
breast cancer or if you have had breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or an abnormal mammogram.</p>
<p>Women who currently have or have had breast cancer should not use oral 
contraceptives because breast cancer is usually a hormone-sensitive tumor.</p>
<p>Some studies have found an increase in the incidence of cancer or 
precancerous lesions of the cervix in women who use oral contraceptives. 
However, this finding may be related to factors other than the use of oral 
contraceptives. There is insufficient evidence to rule out the possibility that 
the pill may cause such cancers.</p>
<p>6. <span class="Bold">Lipid Metabolism and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> of the Pancreas</span></p>
<p>In patients with inherited defects of the lipid metabolism, there have been 
reports of significant elevations of plasma triglycerides during estrogen 
therapy. This has led to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> in some cases.</p>
<p><span class="Bold">ESTIMATED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> FROM A BIRTH CONTROL METHOD OR 
PREGNANCY</span></p>
<p>All methods of birth control and pregnancy are associated with a risk of 
developing certain diseases which may lead to <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. An estimate 
of the number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with different methods of birth control and 
pregnancy has been calculated and is shown in the following table.</p>
<a href="http://"></a><a name="i7a39ead0-2177-4049-872f-2b86ea4c3eeb"></a><table width="451">
<caption><span>ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> ASSOCIATED WITH 
CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY-CONTROL METHOD 
AND ACCORDING TO AGE</span></caption>
<col width="22%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="12%">
<col width="11%">
<col width="13%">
<tbody class="Headless">
<tr class="First"><td><span class="Bold">AGE</span></td></tr>
<tr>
<td>Method of control and outcome 
</td>
<td>15-19 </td>
<td>20-24</td>
<td>25-29</td>
<td>30-34</td>
<td>35-39</td>
<td>40-44</td>
</tr>
<tr>
<td>No fertility -<br>  control 
methods<a href="#footnote-14">*</a>
</td>
<td>7.0</td>
<td>7.4</td>
<td>9.1</td>
<td>14.8</td>
<td>25.7</td>
<td>28.2</td>
</tr>
<tr>
<td>Oral 
contraceptives<br>  non-smoker<a href="#footnote-15">†</a>
</td>
<td>0.3</td>
<td>0.5 </td>
<td>0.9</td>
<td>1.9</td>
<td>13.8</td>
<td>31.6</td>
</tr>
<tr>
<td>Oral 
contraceptives<br>  smoker<a href="#footnote-15">†</a>
</td>
<td>2.2</td>
<td>3.4</td>
<td>6.6</td>
<td>13.5</td>
<td>51.1</td>
<td>117.2</td>
</tr>
<tr>
<td>IUD<a href="#footnote-15">†</a>
</td>
<td>0.8</td>
<td>0.8</td>
<td>1.0</td>
<td>1.0</td>
<td>1.4</td>
<td>1.4</td>
</tr>
<tr>
<td>Condom<a href="#footnote-14">*</a>
</td>
<td>1.1</td>
<td>1.6</td>
<td>0.7</td>
<td>0.2</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Diaphragm/<br>  spermicide<a href="#footnote-14">*</a>
</td>
<td>1.9</td>
<td>1.2</td>
<td>1.2</td>
<td>1.3</td>
<td>2.2</td>
<td>2.8</td>
</tr>
<tr class="Last">
<td>Periodic abstinence<a href="#footnote-14">*</a>
</td>
<td>2.5</td>
<td>1.6</td>
<td>1.6</td>
<td>1.7</td>
<td>2.9</td>
<td>3.6</td>
</tr>
</tbody>
</table>
<a href="#footnote-reference-14">*</a><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth related<a href="#footnote-reference-15">†</a><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method related<br><p>In the above table, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any birth control method is less 
than the risk of childbirth, except for oral contraceptive users over the age of 
35 who smoke and pill users over the age of 40 even if they do not smoke. It can 
be seen in the table that for women aged 15 to 39, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was highest 
with pregnancy (7 to 26 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, depending on age). Among pill 
users who do not smoke, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was always lower than that associated 
with pregnancy for any age group, although over the age of 40, the risk 
increases to 32 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, compared to 28 associated with 
pregnancy at that age. However, for pill users who smoke and are over the age of 
35, the estimated number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> exceeds those for other methods of birth 
control. If a woman is over the age of 40 and smokes, her estimated risk of 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is four times higher (117/100,000 women) than the estimated risk 
associated with pregnancy (28/100,000 women) in that age group.</p>
<p>The suggestion that women over 40 who don't smoke should not take oral 
contraceptives is based on information from older high-dose pills. An Advisory 
Committee of the FDA discussed this issue in 1989 and recommended that the 
benefits of oral contraceptive use by healthy, nonsmoking women over 40 years of 
age may outweigh the possible risks. Older women, as all women who take oral 
contraceptives, should take an oral contraceptive that contains the least amount 
of estrogen and progestin that is compatible with the individual patient 
needs.</p>
<p><span class="Bold">WARNING SIGNALS</span></p>
<p>If any of these adverse effects occur while you are taking oral 
contraceptives, call your healthcare provider immediately:</p>
<ul>
<li>Sharp <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> of blood, or sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> 
(indicating a possible clot in the lung).</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in the calf (indicating a possible clot in the leg).</li>
<li>Crushing <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or heaviness in the chest (indicating a possible heart 
attack).</li>
<li>Sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, disturbances of 
vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg (indicating a possible 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>).</li>
<li>Sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> (indicating a possible clot in the 
eye).</li>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> (indicating possible breast cancer or fibrocystic disease of 
the breast; ask your doctor or healthcare provider to show you how to examine 
your breasts).</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> in the stomach area (indicating a possibly 
ruptured <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span>).</li>
<li>Difficulty in sleeping, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, lack of energy, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or change in mood 
(possibly indicating severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>).</li>
<li><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> or a yellowing of the skin or eyeballs, accompanied frequently by 
<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, loss of appetite, dark-colored urine, or light-colored bowel 
movements (indicating possible liver problems).</li>
</ul>
<p><span class="Bold">SIDE EFFECTS OF ORAL CONTRACEPTIVES</span></p>
<p>In addition to the risks and more serious side effects discussed above (see 
<span class="Bold">RISKS OF TAKING ORAL CONTRACEPTIVES,</span><span class="Bold"> 
ESTIMATED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> FROM A BIRTH CONTROL METHOD OR PREGNANCY </span>and 
<span class="Bold">WARNING SIGNALS </span>sections), the following may also 
occur:</p>
<p>1. <span class="Bold">Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></p>
<p>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting between your 
expected period) is likely to occur while you are taking Jolessa<span class="Sup">™</span>. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may vary from slight staining between 
menstrual periods to breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which is a flow much like a regular 
period. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs most often during the first few 91-day cycles 
of Jolessa<span class="Sup">™</span> use, tends to decrease during later cycles, 
but may also occur after you have been taking Jolessa<span class="Sup">™</span> 
for some time. Such <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> usually does not indicate any serious problems. 
<span class="Bold">It is important to continue taking your pills on schedule even 
if you are having irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span>. If the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> lasts for more than 
7 consecutive days, talk to your healthcare provider.</p>
<p>When you take Jolessa<span class="Sup">™</span>, you need to consider the 
convenience of fewer expected menstrual periods (4 per year instead of 13) and 
the inconvenience of more irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting. In a clinical 
trial comparing Jolessa<span class="Sup">™</span> (91-day cycles) to a 
conventional equivalent dosage 28-day cycle oral contraceptive, more women using 
Jolessa<span class="Sup">™</span> discontinued treatment because of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> 
problems (7.7% of the Jolessa<span class="Sup">™</span> users compared to 1.8% of 
the 28-day cycle users).</p>
<p>The following Table shows the percentages of women with 7 or more and 20 or 
more days of <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span> and/or spotting in the Jolessa<span class="Sup">™</span> and the 28-day cycle treatment groups.</p>
<a href="http://"></a><a name="ife3f5d47-760f-4fe8-8542-3f265ced7750"></a><table width="431">
<caption><span>Percentages (%) of Women with <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">Intermenstrual Bleeding</span> and/or 
Spotting</span></caption>
<col width="39%">
<col width="27%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td>Number of days of 
<span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span> and/or spotting</td>
<td>Percentage of subjects 
with<br><span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span> or spotting<a href="#footnote-16">*</a>
</td>
</tr>
<tr>
<td><span class="Bold">Jolessa<span class="Sup">™</span></span></td>
<td>Cycle 1</td>
<td>Cycle 4</td>
</tr>
<tr>
<td> 7 or more days</td>
<td>65%</td>
<td>42%</td>
</tr>
<tr>
<td> 20 or more days</td>
<td>35%</td>
<td>15%</td>
</tr>
<tr>
<td><span class="Bold">28-day 
cycle pill</span></td>
<td>Cycles 1-4</td>
<td>Cycles 10-13</td>
</tr>
<tr>
<td> 7 or more</td>
<td>38%</td>
<td>39%</td>
</tr>
<tr class="Last">
<td> 20 or more days</td>
<td>6%</td>
<td>4%</td>
</tr>
</tbody>
</table>
<a href="#footnote-reference-16">*</a>Based on spotting and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on days 1-84 of a 91 day cycle in the 
Jolessa<span class="Sup">™</span> subjects and days 1-21 of a 28 day cycle over 4 
cycles in the 28-day dosing regimen.<br><p>Total days of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting (withdrawal plus intermenstrual) were 
similar over one year of treatment for Jolessa<span class="Sup">™</span> subjects 
and subjects on the 28-day cycle regimen.</p>
<p>2. <span class="Bold">Contact lenses</span></p>
<p>If you wear contact lenses and notice a change in vision or an inability to 
wear your lenses, contact your healthcare provider.</p>
<p>3. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></span></p>
<p>Oral contraceptives may cause <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the 
fingers or ankles and may raise your blood pressure. If you experience fluid 
retention, contact your healthcare provider.</p>
<p>4. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span></span></p>
<p>A spotty darkening of the skin is possible, particularly of the face.</p>
<p>5. <span class="Bold">Other side effects</span></p>
<p>Other side effects may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, change in appetite, 
<span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of scalp 
hair, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infections</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<p>If any of these side effects bother you, call your healthcare provider.</p>
<p><span class="Bold">GENERAL PRECAUTIONS</span></p>
<p>1. <span class="Bold">Missed Periods and Use of Oral Contraceptives Before or 
During Early Pregnancy</span></p>
<p><span class="Bold">If you miss any periods (no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on the days that you 
take white pills), you must consider the possibility that you may be pregnant. 
</span>Notify your healthcare provider that you are taking Jolessa<span class="Sup">™</span> and have missed your period. Also notify your healthcare 
provider if you have any symptoms of pregnancy such as morning sickness or 
unusual <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>. Because you are taking Jolessa<span class="Sup">™</span>, it is very important that your healthcare provider evaluates 
you to determine if you are pregnant. Stop taking Jolessa<span class="Sup">™</span> if you are pregnant.</p>
<p>There is no conclusive evidence that oral contraceptive use is associated 
with an increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, when taken inadvertently during early 
pregnancy. Previously, a few studies had reported that oral contraceptives might 
be associated with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, but these studies have not been confirmed. 
Nevertheless, oral contraceptives should not be used during pregnancy. You 
should check with your healthcare provider about risks to your unborn child of 
any medication taken during pregnancy.</p>
<p>2. <span class="Bold">While Breastfeeding</span></p>
<p>If you are breastfeeding, consult your healthcare provider before starting 
oral contraceptives. Some of the drug will be passed on to the child in the 
milk. A few adverse effects on the child have been reported, including yellowing 
of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives 
may decrease the amount and quality of your milk. If possible, do not use oral 
contraceptives while breastfeeding. You should use another method of 
contraception since breastfeeding provides only partial protection from becoming 
pregnant and this partial protection decreases significantly as you breast-feed 
for longer periods of time. You should consider starting oral contraceptives 
only after you have weaned your child completely.</p>
<p>3. <span class="Bold">Laboratory Tests</span></p>
<p>If you are scheduled for any laboratory tests, tell your healthcare provider 
you are taking birth control pills. Certain blood tests may be affected by birth 
control pills.</p>
<p>4. <span class="Bold">Drug Interactions</span></p>
<p>Certain drugs may interact with birth control pills to make them less 
effective in preventing pregnancy or cause an increase in breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. 
Such drugs include rifampin, drugs used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> such as barbiturates (for 
example, phenobarbital), carbamazepine (Tegretol is one brand of this drug), and 
phenytoin (Dilantin<span class="Sup">®</span> is one brand of this drug), 
primidone (Mysoline<span class="Sup">®</span>), topiramate (Topamax<span class="Sup">®</span>), phenylbutazone (Butazolidin<span class="Sup">®</span> is one 
brand), some drugs used for HIV such as ritonavir (Norvir<span class="Sup">®</span>), modafinil (Provigil<span class="Sup">®</span>) and possibly 
certain antibiotics (such as ampicillin and other penicillins, and 
tetracyclines). Pregnancies and breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported by 
users of combined hormonal contraceptives who also used some form of the herbal 
supplement St. John’s Wort. You may need to use a non-hormonal method of 
contraception during any cycle in which you take drugs that can make oral 
contraceptives less effective. Be sure to tell your healthcare provider if you 
are taking or start taking any other medications, including nonprescription 
products or herbal products while taking birth control pills.</p>
<p>You may be at higher risk of a specific type of liver dysfunction if you take 
troleandomycin and oral contraceptives at the same time.</p>
<p>Birth control pills may interact with lamotrigine, an anticonvulsant used for 
<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. This may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, so your physician may need to 
adjust the dose of lamotrigine.</p>
<p>5. <span class="Bold"><span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually transmitted diseases</span></span></p>
<p>This product (like all oral contraceptives) is intended to prevent pregnancy. 
It does not protect against transmission of HIV (AIDS) and other sexually 
transmitted diseases such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, 
<span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</p>
<p><span class="Bold">What You Should Know About Your Menstrual Cycle When Taking 
Jolessa<span class="Sup">™</span></span></p>
<p>When you take Jolessa<span class="Sup">™</span>, which has a 91-day treatment 
cycle, you should expect to have 4 menstrual periods per year (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when you 
are taking the 7 white pills). However, you also should expect to have more 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting between your menstrual periods than if you were taking an 
oral contraceptive with a 28-day treatment cycle. During the first Jolessa<span class="Sup">™</span> treatment cycle, about 1 in 3 women may have 20 or more days 
of unplanned <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when you are taking pink pills). 
This <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting tends to decrease during later cycles. Do not stop 
Jolessa<span class="Sup">™</span> because of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If the spotting 
continues for more than 7 consecutive days or if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is heavy, call 
your healthcare provider.</p>
<p><span class="Bold">HOW TO TAKE JOLESSA<span class="Sup">™</span></span></p>
<p><span class="Bold">IMPORTANT POINTS TO REMEMBER <span class="Italics">BEFORE</span> YOU START TAKING JOLESSA<span class="Sup">™</span></span></p>
<ol>
<li>BE SURE TO READ THESE DIRECTIONS:<br>• Before you start taking your 
pills.<br>• Anytime you are not sure what to do.</li>
<li>THE RIGHT WAY TO TAKE JOLESSA<span class="Sup">™</span> IS TO TAKE ONE PILL 
EVERY DAY AT THE SAME TIME.<br>If you miss pills you could get pregnant. This 
includes starting the pack late. The more pills you miss, the more likely you 
are to get pregnant.</li>
<li>MANY WOMEN MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST FEW WEEKS OF 
TAKING PILLS.<br>If you feel sick to your stomach, do not stop taking the pill. 
The problem will usually go away. If it doesn't go away, check with your 
healthcare provider.</li>
<li>MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> DURING THE FIRST FEW MONTHS OF 
TAKING JOLESSA<span class="Sup">™</span>. <span class="Bold">Do not stop taking your 
pills even if you are having irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span>. If the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> lasts 
for more than a few days, talk to your healthcare provider.</li>
<li>MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make 
up these missed pills.<br>On the days you take 2 pills to make up for missed 
pills, you could also feel a little sick to your stomach.</li>
<li>IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, or IF YOU TAKE SOME MEDICINES, including 
some antibiotics and the herbal supplement St. John’s Wort, Jolessa<span class="Sup">™</span> may not work as well. Use a back-up method (such as condoms 
or spermicides) until you check with your healthcare provider.</li>
<li>IF YOU HAVE TROUBLE REMEMBERING TO TAKE JOLESSA<span class="Sup">™</span>, 
talk to your healthcare provider about how to make pill-taking easier or about 
using another method of birth control.</li>
<li>IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS 
LEAFLET, call your healthcare provider.</li>
</ol>
<p><span class="Bold"><span class="Italics">BEFORE</span> YOU START TAKING 
JOLESSA<span class="Sup">™</span></span></p>
<ol>
<li>DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take 
it at about the same time every day.</li>
<li>LOOK AT YOUR EXTENDED-CYCLE TABLET DISPENSER. Your Tablet Dispenser consists 
of 3 trays with cards that hold 91 individually sealed pills (a 13-week or 
91-day cycle). The 91 pills consist of 84 pink pills (active pills with 
hormones) and 7 white pills, (inactive pills without hormone). Trays 1 and 2 
each contain 28 pink pills (4 rows of 7 pills). Tray 3 contains 35 pills 
consisting of 28 pinks pills (4 rows of 7 pills) and 7 white pills (1 row of 7 
pills).<div class="Figure"><img alt="image of dispenser" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=709031e4-4c20-4ea7-beff-6c459709a433&amp;name=dispenser.jpg"></div>
</li>
<li>ALSO FIND:<br>• Where on the first row in the pack to start taking pills 
(upper left corner at the start arrow) and<br>• In what order to take the pills 
(follow the weeks and arrow).</li>
<li>BE SURE YOU HAVE READY AT ALL TIMES ANOTHER KIND OF BIRTH CONTROL (such as 
condoms or spermicides), to use as a back-up in case you miss pills.</li>
</ol>
<p><span class="Bold">WHEN TO START JOLESSA<span class="Sup">™</span></span></p>
<ol>
<li>Take the first “active? pink pill on the Sunday after your period starts, 
even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start the first 
pink pill that same day.</li>
<li>Use another method of birth control (such as condom or spermicide) as a 
back-up method if you have sex anytime from the Sunday you start your first pink 
pill until the next Sunday (first 7 days).</li>
</ol>
<p><span class="Bold">HOW TO TAKE JOLESSA<span class="Sup">™</span></span></p>
<ol>
<li>
<span class="Bold">Take one pill at the same time every day until you have 
taken the last pill in the tablet dispenser.<br><span class="Underline">Do not 
skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></span> or feel sick to 
your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).<br>Do not skip pills even if you do not have sex very 
often.</li>
<li>
<span class="Bold">WHEN YOU FINISH A TABLET DISPENSER.</span><br>After taking 
the last white pill, start taking the first pink pill from a new Extended-Cycle 
Tablet Dispenser <span class="Bold">the very next day </span>regardless of when 
your period started. This should be on a Sunday.</li>
<li>
<span class="Bold">If you miss your period when you are taking the white 
pills, call your healthcare provider because you may be 
pregnant</span>.</li>
</ol>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1 </span>pink “active? pill:</p>
<ol>
<li>Take it as soon as you remember. Take the next pill at your regular time. 
This means you may take 2 pills in 1 day.</li>
<li>You do not need to use a back-up birth control method if you have 
sex.</li>
</ol>
<p>If you <span class="Bold">MISS 2 </span>pink “active? pills in a row:</p>
<ol>
<li>Take 2 pills on the day you remember, and 2 pills the next day.</li>
<li>Then take 1 pill a day until you finish the pack.</li>
<li>You COULD BECOME PREGNANT if you have sex in the 7 days after you restart 
your pills. You MUST use another birth control method (such as condoms or 
spermicide) as a back-up on the 7 days after you restart your pills.</li>
</ol>
<p>If you <span class="Bold">MISS 3 OR MORE </span>pink “active? pills in a 
row:</p>
<ol>
<li>Do not remove the missed pills from the pack as they will not be taken. Keep 
taking 1 pill every day as indicated on the pack until you have completed all of 
the remaining pills in the pack. For example: If you resume taking the pill on 
Thursday, take the pill under “Thursday? and do not take the missed pills. You 
may experience <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during the week following the missed pills.</li>
<li>You COULD BECOME PREGNANT if you have sex during the days of missed pills or 
during the first 7 days after restarting your pills.</li>
<li>You <span class="Bold">must </span>use a non-hormonal birth control method 
(such as condoms or spermicide) as a back-up when you miss pills and for the 
first 7 days after you restart your pills. <span class="Bold">If you miss your 
period when taking the white pills, call your healthcare provider because you 
may be pregnant.</span>
</li>
</ol>
<p>If you <span class="Bold">MISS ANY </span>of the 7 white inactive pills.</p>
<ol>
<li>Throw away the missed pills.</li>
<li>Keep taking the scheduled pills until the pack is finished.</li>
<li>You do not need a back-up method of birth control.</li>
</ol>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE 
PILLS YOU HAVE MISSED</span></p>
<ol>
<li>Use a BACK-UP METHOD anytime you have sex.</li>
<li>KEEP TAKING ONE PILL EACH DAY until you contact your healthcare 
provider.</li>
</ol>
<p><span class="Bold">PREGNANCY DUE TO PILL FAILURE</span></p>
<p>If taken every day as directed, the incidence of pill failure resulting in 
pregnancy is approximately 1% (ie, one pregnancy per 100 women per year), but 
more typical failure rates are about 5%. If failure does occur, the risk to the 
fetus is minimal.</p>
<p><span class="Bold">PREGNANCY AFTER STOPPING THE PILL</span></p>
<p>There may be some delay in becoming pregnant after you stop using oral 
contraceptives, especially if you had <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstrual cycles</span> before you used 
oral contraceptives. It may be advisable to postpone conception until you begin 
menstruating regularly once you have stopped taking the pill and desire 
pregnancy.</p>
<p>There does not appear to be any increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in newborn babies 
when pregnancy occurs soon after stopping the pill.</p>
<p><span class="Bold">OVERDOSAGE</span></p>
<p>Serious ill effects have not been reported following ingestion of large doses 
of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and 
<span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in females. In case of overdosage, contact your healthcare 
provider or pharmacist.</p>
<p><span class="Bold">OTHER INFORMATION</span></p>
<p>Your healthcare provider will take a medical and family history before 
prescribing oral contraceptives and will examine you. The physical examination 
may be delayed to another time if you request it and the healthcare provider 
believes that it is appropriate to postpone it. You should be reexamined at 
least once a year. Be sure to inform your healthcare provider if there is a 
family history of any of the conditions listed previously in this leaflet. Be 
sure to keep all appointments with your healthcare provider, because this is a 
time to determine if there are early signs of side effects of oral contraceptive 
use.</p>
<p>Do not use the drug for any condition other than the one for which it was 
prescribed. This drug has been prescribed specifically for you; do not give it 
to others who may want birth control pills.</p>
<p><span class="Bold">NONCONTRACEPTIVE HEALTH BENEFITS</span></p>
<p>The following noncontraceptive health benefits related to the use of oral 
contraceptives are supported by epidemiological studies which largely utilized 
oral contraceptive formulations containing doses exceeding 0.035 mg of ethinyl 
estradiol or 0.05 mg of mestranol.</p>
<p>Effects on menses:</p>
<ul>
<li>May decrease blood loss and may decrease incidence of iron-deficiency 
<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></li>
<li>May decrease incidence of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span></li>
</ul>
<p>Effects related to inhibition of ovulation:</p>
<ul>
<li>May decrease incidence of functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span></li>
<li>May decrease incidence of ectopic pregnancies</li>
</ul>
<p>Effects from long-term use:</p>
<ul>
<li>May decrease incidence of fibroadenomas and fibrocystic disease of the 
breast</li>
<li>May decrease incidence of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span></li>
<li>May decrease incidence of endometrial cancer</li>
<li>May decrease incidence of ovarian cancer</li>
</ul>
<p>If you want more information about birth control pills, ask your doctor or 
pharmacist. They have a more technical leaflet called the Professional Labeling 
which you may wish to read.</p>
<p><br><span class="Bold">BARR LABORATORIES, INC.</span></p>
<p><span class="Bold">Pomona, NY 10970</span></p>
<p><br>Revised February 2010</p>
<p>11001623</p>
<p><br></p>
<p><span class="Bold">Relabeling of Additional barcode label by:</span></p>
<p>Physicians Total Care, Inc.<br>Tulsa, OK        74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">1 Extended-Cycle Tablet Dispensers</p>
<p>91 Tablets Each      91 DAY REGIMEN</p>
<p>NDC 54868-6044-0</p>
<p><img alt="image of 0.15/0.3 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=709031e4-4c20-4ea7-beff-6c459709a433&amp;name=6044.jpg"></p>
<p>Jolessa<span class="Sup">TM</span><br>(levonorgestrel / ethinyl estradiol 
tablets) 0.15 mg/0.03 mg</p>
<p>Contains 1 Extended-Cycle Tablet Dispensers, each containing 91 tablets: 84 
<br>pink tablets, each containing 0.15 mg levonorgestrel with 0.03 mg 
ethinyl<br>estradiol, and 7 white inert tablets.</p>
<p>Rx only</p>
<p>Store at 20° to 25°C (68° to 77°F)<br>[See USP Controlled Room 
Temperature].</p>
<p>Usual Dosage: One tablet daily for 91 consecutive days in the following 
order: 84 pink tablets followed by 7 white tablets as prescribed.</p>
<p>See enclosed package brochure.</p>
<p>Pharmacist: Dispense patient information with each prescription.</p>
<p>THIS PRODUCT (LIKE ALL ORAL CONTRACEPTIVES) IS INTENDED TO PREVENT PREGNANCY. 
IT DOES NOT PROTECT AGAINST <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV INFECTION</span> (AIDS) AND OTHER SEXUALLY TRANSMITTED 
DISEASES.</p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>JOLESSA 		
					</strong><br><span class="contentTableReg">levonorgestrel and ethinyl estradiol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6044(NDC:0555-9123)</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6044-0</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">84 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>JOLESSA 		
					</strong><br><span class="contentTableReg">levonorgestrel and ethinyl estradiol tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVONORGESTREL</strong> (LEVONORGESTREL) </td>
<td class="formItem">LEVONORGESTREL</td>
<td class="formItem">0.15 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.03 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (15000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b;992</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021544</td>
<td class="formItem">06/24/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>INERT 		
					</strong><br><span class="contentTableReg">inert tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (15000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b;208</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021544</td>
<td class="formItem">06/24/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021544</td>
<td class="formItem">06/24/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>edb90de8-4b9c-4e69-b3a2-1bb5eaaff306</div>
<div>Set id: 709031e4-4c20-4ea7-beff-6c459709a433</div>
<div>Version: 1</div>
<div>Effective Time: 20110128</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
